

BEST AVAILABLE COPY

10743642

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:02:12 ON 04 FEB 2007

=> FILE REG

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 15:02:25 ON 04 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 FEB 2007 HIGHEST RN 919200-33-2

DICTIONARY FILE UPDATES: 2 FEB 2007 HIGHEST RN 919200-33-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:



<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10743642.str

SAEED

10743642



chain nodes :
6 7 8 9 12 13 16
ring nodes :
1 2 3 4 5
chain bonds :
1-8 3-6 5-13 6-7 6-12 7-16 8-9
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 1-8 2-3 3-4 3-6 4-5 5-13 6-7 6-12 7-16 8-9
isolated ring systems :
containing 1 :

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:Atom 12:CLASS
13:Atom 16:CLASS

L1 STRUCTURE UPLOADED


SAEED

10743642

=> D

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> S L1

SAMPLE SEARCH INITIATED 15:02:47 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 3640 TO ITERATE

54.9% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

41 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 69182 TO 76418
PROJECTED ANSWERS: 974 TO 2010



L2 41 SEA SSS SAM L1

=>

Uploading C:\Program Files\Stnexp\Queries\107436421.str

SAEED

10743642



chain nodes :
6 7 8 9 12 13 16
ring nodes :
1 2 3 4 5
chain bonds :
1-8 3-6 5-13 6-7 6-12 7-16 8-9
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 1-8 2-3 3-4 3-6 4-5 5-13 6-7 6-12 7-16 8-9
isolated ring systems :
containing 1 :

G1:C,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:Atom 12:CLASS
13:Atom 16:CLASS

L3 STRUCTURE UPLOADED

SAEED

10743642

=> D
L3 HAS NO ANSWERS
L3 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> S L3
SAMPLE SEARCH INITIATED 15:04:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3640 TO ITERATE

54.9% PROCESSED 2000 ITERATIONS 41 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 69182 TO 76418
PROJECTED ANSWERS: 974 TO 2010

L4 41 SEA SSS SAM L3

=> S L3 FULL
FULL SEARCH INITIATED 15:04:43 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 72017 TO ITERATE

100.0% PROCESSED 72017 ITERATIONS 1282 ANSWERS
SEARCH TIME: 00.00.01

L5 1282 SEA SSS FUL L3

=> FILE CAPLUS
COST IN U.S. DOLLARS
FULL ESTIMATED COST
SINCE FILE ENTRY 173.45
TOTAL SESSION 173.66

FILE 'CAPLUS' ENTERED AT 15:04:53 ON 04 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

SAEED

10743642

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Feb 2007 VOL 146 ISS 7
FILE LAST UPDATED: 2 Feb 2007 (20070202/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> S L5

L6 43 L5

=> D IBIB ABS HITSTR TOT

10743642

L6 ANSWER 1 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:11808 CAPLUS
DOCUMENT NUMBER: 146:121964
TITLE: Imidazole based LXR modulators and their preparation, pharmaceutical compositions and use in the treatment of diseases
INVENTOR(S): Busch, Breet B.; Platt, Brenton T.; Gu, Xiao Hui; Lu, Shao Po; Martin, Richard; Mohan, Raju; Nyman, Michael Charles; Schweiger, Edwin; Stevens, William C., Jr.; Wang, Tie Lin; Xie, Yining
PATENT ASSIGNEE(S): Exelixis, Inc., USA
SOURCE: PCT Int. Appl., 268pp., which
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007002563	A1	20070104	WO 2006-US24757	20060626
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPL. INFO.:		US 2005-694372P	P	20050627
		US 2005-736120P	P	20051110

GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Comps. of the invention, such as comps. of formulas I, II, III and IV and pharmaceutically acceptable salts, isomers, and prodrugs thereof, are useful as modulators of the activity of liver X receptors.

Pharmaceutical comps. containing the comps. and methods of using the comps. are also disclosed. Comps. of formulas I - IV wherein R1 is (un)substituted (hetero)aryl, (un)substituted C3-8 cycloalkyl, (un)substituted alkyl, (un)substituted acyl, (un)substituted thioacyl, sulfonyl, ether, etc.; R2 and R21 are independently (un)substituted alkyl, (un)substituted alkylidyl, H, halo, NO2, (hetero)aryl, etc.; R3 is (un)substituted alkyl, (un)substituted alkylidyl, (un)substituted (hetero)aryl, CN, etc.; G is (un)substituted (hetero)aryl, (un)substituted (hetero)biaryl,


L6 ANSWER 1 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(un)substituted alkylaryl, etc.; and their pharmaceutically acceptable salts, isomers, and prodrugs thereof are claimed. Example compd. V was prepd. by addn. of 2,5-dichloroaniline to
5-bromothiophene-2-carbonitrile;
the resulting 5-bromo-N-(2,5-dichlorophenyl)thiophene-2-carboxamide underwent cyclization with 1-bromo-3,3,3-trifluoroacetone to give
2-(5-bromothiophen-2-yl)-1-(2,5-dichlorophenyl)-4-trifluoromethyl-4,5-dihydro-1H-imidazol-4-ol, which underwent dehydration to give 2-(5-bromothiophen-2-yl)-1-(2,5-dichlorophenyl)-4-trifluoromethyl-1H-imidazole, which underwent Suzuki cross-coupling with 3-methylsulfonylphenylboronic acid to
give compd. V. All the invention comps. were evaluated for their LXR modulatory activity. From the assay, it was detd. that several of the tested compd. exhibited IC50 values of < 1 μ M. Comps. of the invention, such as comps. of Formulas Ia, Ib, Ic, or Id and pharmaceutically acceptable salts, isomers, and prodrugs thereof, which are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3, and G are defined herein. Pharmaceutical comps. contg. the comps. and methods of using the comps. are also disclosed.
IT 918348-89-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate and intermediate; preparation of imidazole based LXR modulators and their use in the treatment of diseases)

RN 918348-89-7 CAPLUS
CN 1H-Imidazole-4-carboxamide,
2-(2-chlorophenyl)-1-[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




IT 918348-90-0P 918348-91-1P 918348-92-2P
918348-93-3P 918348-94-4P 918348-95-5P
918348-96-6P 918348-98-8P 918348-99-9P
918349-00-5P 918349-01-6P 918349-02-7P

L6 ANSWER 1 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
918349-03-8P 918349-04-9P 918349-05-0P
918349-06-1P 918349-07-2P 918349-08-3P
918349-09-4P 918349-10-7P 918349-11-8P
918349-12-9P 918349-35-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of imidazole based LXR modulators and their use in the treatment of diseases)
RN 918348-90-0 CAPLUS
CN 1H-Imidazole-4-carboxamide, 2-[2-(1-methylethyl)phenyl]-1-[3-methyl-3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 918348-91-1 CAPLUS
CN 1H-Imidazole-4-carboxamide, 2-(2,6-dichlorophenyl)-1-[3-methyl-3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)

L6 ANSWER 1 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 918348-92-2 CAPLUS
CN 1H-Imidazole-4-carboxamide,
2-(2,6-dichlorophenyl)-1-[3'-(methylsulfonyl)-3-methyl[1,1'-biphenyl]-4-yl]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 918348-93-3 CAPLUS
CN 1H-Imidazole-4-carboxamide,
2-(2,6-dichlorophenyl)-N,N-diethyl-1-[3-methyl-3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)

10743642

L6 ANSWER 1 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 918348-94-4 CAPLUS
 CN 1H-imidazole-4-carboxamide, 2-(2,6-dichlorophenyl)-1-[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 918348-95-5 CAPLUS
 CN 1H-imidazole-4-carboxamide, 2-(2,6-dichlorophenyl)-N-(2-fluoroethyl)-1-[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)

L6 ANSWER 1 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 918348-99-9 CAPLUS
 CN 1H-imidazole-4-carboxamide, 1-[3-chloro-3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-(2,6-dichlorophenyl)-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 918349-00-5 CAPLUS
 CN 1H-imidazole-4-carboxamide, 1-[3-chloro-3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-(2,6-dichlorophenyl)-N-(2-fluoroethyl)- (CA INDEX NAME)

L6 ANSWER 1 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 918348-96-6 CAPLUS
 CN 1H-imidazole-4-carboxamide, 2-(2,6-dichlorophenyl)-N-ethyl-1-[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)




RN 918348-98-8 CAPLUS
 CN 1H-imidazole-4-carboxamide, 2-(2,6-dichlorophenyl)-N-(2-hydroxyethyl)-1-[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)

L6 ANSWER 1 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 918349-01-6 CAPLUS
 CN Glycine, N-([1-[3-chloro-3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-(2,6-dichlorophenyl)-1H-imidazol-4-yl]carbonyl)- (CA INDEX NAME)




RN 918349-02-7 CAPLUS
 CN 1H-imidazole-4-carboxamide, 1-[3-chloro-3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-(2,6-dichlorophenyl)-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)


SAAED

10743642

L6 ANSWER 1 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 918349-03-8 CAPLUS
 CN 1H-Imidazole-4-carboxamide,
 1-([3-chloro-3'-(methylsulfonyl)-1,1'-biphenyl]-
 4-yl)-2-(2,6-dichlorophenyl)-N-(2-hydroxy-1,1-dimethylethyl)- (CA INDEX
 NAME)




RN 918349-04-9 CAPLUS
 CN 1H-Imidazole-4-carboxamide,
 1-([3-chloro-3'-(ethylsulfonyl)-1,1'-biphenyl]-
 4-yl)-2-(2,6-dichlorophenyl)-N-(2-hydroxy-1,1-dimethylethyl)- (CA INDEX
 NAME)

L6 ANSWER 1 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 918349-07-2 CAPLUS
 CN 1H-Imidazole-4-carboxamide,
 1-([3-chloro-3'-(ethylsulfonyl)-1,1'-biphenyl]-
 4-yl)-2-(2,6-dichlorophenyl)-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 918349-08-3 CAPLUS
 CN 1H-Imidazole-4-carboxamide,
 1-([3-chloro-3'-(methylsulfonyl)-1,1'-biphenyl]-
 4-yl)-2-(2,6-dichlorophenyl)-N-(2-hydroxy-2-methylpropyl)- (CA INDEX
 NAME)

L6 ANSWER 1 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 918349-05-0 CAPLUS
 CN 1H-Imidazole-4-carboxamide,
 1-([3-chloro-3'-(methylsulfonyl)-1,1'-biphenyl]-
 4-yl)-2-(2,6-dichlorophenyl)-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 918349-06-1 CAPLUS
 CN 1H-Imidazole-4-carboxamide,
 1-([3-chloro-3'-(methylsulfonyl)-1,1'-biphenyl]-
 4-yl)-2-(2,6-dichlorophenyl)-N-(2-hydroxyethyl)- (CA INDEX NAME)

L6 ANSWER 1 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 918349-09-4 CAPLUS
 CN 1H-Imidazole-4-carboxamide,
 1-([3-chloro-3'-(ethylsulfonyl)-1,1'-biphenyl]-
 4-yl)-2-(2,6-dichlorophenyl)-N-(2-hydroxy-2-methylpropyl)- (CA INDEX
 NAME)




RN 918349-10-7 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 2-(2,6-dichlorophenyl)-N-(2-hydroxy-1,1-
 dimethylethyl)-1-([3'-(methylsulfonyl)-1,1'-biphenyl]-4-yl)- (CA INDEX
 NAME)

10743642

L6 ANSWER 1 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 918349-11-8 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 2-(2,6-dichlorophenyl)-1-[3'-(ethylsulfonyl)[1,1'-biphenyl]-4-yl]-N-(2-hydroxy-1,1-dimethylethyl)-
 (CA INDEX NAME)




RN 918349-12-9 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 2-(2,6-dichlorophenyl)-N-(1,1-dimethylethyl)-1-[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-
 (CA INDEX NAME)

L6 ANSWER 1 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 trifluoroethyl)- (CA INDEX NAME)




REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L6 ANSWER 1 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 918349-35-6 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 1-[3-chloro-3'-(1-hydroxy-1-methylethyl)[1,1'-biphenyl]-4-yl]-2-(2,6-dichlorophenyl)-N-(2-hydroxy-1,1-dimethylethyl)-
 (CA INDEX NAME)



IT 918350-02-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of imidazole based LXR modulators and
 their use in the treatment of diseases)
 RN 918350-02-4 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 1-(4-bromophenyl)-2-(2-chlorophenyl)-N-(2,2,2-

L6 ANSWER 2 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1190030 CAPLUS
 TITLE: Xanthine mimetics as potent dipeptidyl peptidase IV inhibitors
 AUTHOR(S): Kurukulasuriya, Ravi; Rohde, Jeffrey J.; Szczepankiewicz, Bruce G.; Basha, Fatima; Lai, Chunqiu; Jee, Hwan-Soo; Winn, Martin; Stewart, Kent D.; Longenecker, Kanton L.; Lubben, Thomas W.; Ballaron, Stephen J.; Sham, Hing L.; von Geldern, Thomas W.
 CORPORATE SOURCE: Metabolic Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL, 60064-6098, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(24), 6226-6230
 CODEN: BMCLB; ISSN: 0960-894X
 PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Aminopiperidinyl-substituted fused imidazoles such as pyrroloimidazole I-HCl are prepared as xanthine mimetics using a copper-catalyzed cyclocondensation of bromoaryl guanidines as the key step; their inhibition of human dipeptidylpeptidase IV (DPP-IV) and the selectivities of some of the compds. for DPP-IV over DPP-8, DPP-9, and prolyl oligopeptidase are determined. I binds to human DPP-IV with a K_i value of 2 nM while binding to DPP-8, DPP-9, and prolyl oligopeptidase with K_i values $> 3 \mu\text{M}$. I is poorly bioavailable in rats, with a high clearance, low oral bioavailability, and low stability in the presence of rat plasma. Imidazololedicarboxamide II and an imidazololedicarboxamide related to I are prepared; II binds to DPP-IV with a K_i value of 11 nM while binding to DPP-8, DPP-9, and prolyl oligopeptidase with K_i values $> 3 \mu\text{M}$ and while being significantly more potent than I in the presence of plasma. I is not selective for human DPP-IV over rat DPP-IV. The crystal structure of I bound to human DPP-IV is determined by X-ray crystallog. IT 918931-49-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of a aminopiperidinyl imidazololedicarboxamide with improved plasma stability as an inhibitor of human dipeptidylpeptidase IV and

SAAED


10743642

L6 ANSWER 2 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
its selectivity for DPPIV over DPP8, DPP9, and prolyl oligopeptidase)
RN 918931-49-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



● HCl

IT 918931-46-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of a aminopiperidinyl imidazoledicarboxamide with improved plasma stability as an inhibitor of human dipeptidylpeptidase IV and its selectivity for DPPIV over DPP8, DPP9, and prolyl oligopeptidase)
RN 918931-46-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




IT 918931-47-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of an aminopiperidinyl imidazopyridazinedione with improved

L6 ANSWER 3 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:845225 CAPLUS
DOCUMENT NUMBER: 145:271779
TITLE: Preparation of 1H-imidazole derivatives for use as modulators in the treatment of disorders involving cannabinoid CB2 receptors
INVENTOR(S): Lange, Josephus H., M.; Stuijvenberg, Herman H.; Van Vliet, Bernard J.
PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V., Neth.
SOURCE: PCT Int. Appl., Bipp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006087355	A1	20060824	WO 2006-EP60009	20060216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006194779	A1	20060831	US 2006-353155	20060214
PRIORITY APPLN. INFO.:			EP 2005-101171	A 20050216
			US 2005-653091P	P 20050216


OTHER SOURCE(S): MARPAT 145:271779
Q1



AB 1H-imidazole derivs. I, wherein R1 is H, halogen, (un)substituted alkyl, (un)substituted alkynyl, (un)substituted alkenyl, acetyl, cyclopropyl; R2 is (un)substituted Ph, (un)substituted heteroaryl, 4-10 membered monocyclic, fused bicyclic or fused tricyclic carbocyclic ring; R3 H, halogen, alkylsulfonyl, (un)substituted heteroaryl; R4 is an (un)substituted ketone or (un)substituted amide are prepared as modulators for the treatment of disorders in which cannabinoid CB2 receptors are

SAAED

L6 ANSWER 2 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
plasma stability as an inhibitor of human dipeptidylpeptidase IV and its selectivity for DPPIV over DPP8, DPP9, and prolyl oligopeptidase)
RN 918931-47-2 CAPLUS
CN 1H-imidazole-5-carboxylic acid, 1-[(2-cyanophenyl)methyl]-2-[3-[[[(1,1-dimethylethoxy)carbonylamino]cyclohexyl]-4-[(methylamino)carbonyl]-, 1,2-dimethylhydrazide] (CA INDEX NAME)




REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L6 ANSWER 3 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
involved. Thus, II was prepd. and tested as for the in vitro affinity for

human cannabinoid CB1 and CB2 receptors (pKi <6.0 and 7.3 resp.). Further, I can be used in the treatment of neuropathic pain, cancers, allergies, multiple sclerosis, Huntington's disease, inflammatory and immune system disorders.

IT 906804-65-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1H-imidazole derivs. for use as modulators in treatment of disorders involving cannabinoid CB2 receptors)
RN 906804-65-7 CAPLUS
CN 1H-imidazole-4-carboxamide, 2-cyclopropyl-5-methyl-1-phenyl-N-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE


10743642

L6 ANSWER 4 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:793003 CAPLUS
 DOCUMENT NUMBER: 145:230632
 TITLE: Preparation of amide compounds as diacylglycerol acyltransferase inhibitors
 INVENTOR(S): Ogino, Masaki; Nakada, Yoshihisa; Shimada, Mitsuyuki; Asano, Kouhei; Tamura, Norikazu; Masago, Minoru
 PATENT ASSIGNER(S): Takeda Pharmaceutical Company Limited, Japan
 SOURCE: PCT Int. Appl., 299pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006082952	A1	20060810	WO 2006-JP301943	20060131
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TO, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPL. INFO.: JP 2005-25713 A 20050201


OTHER SOURCE(S): MARPAT 145:230632
 GI




AB The title compds. I (ring A represents an optionally substituted ring (which is not a pyrrolidine, piperidine or piperazine); ring B represents an optionally substituted aromatic ring; ring D represents an optionally substituted ring; R1 and R2 independently represent a hydrogen atom or a substituent; R3 represents a hydrogen atom or a C1-6 alkyl group, or alternatively it combines with the ring A to form a non-aromatic ring; excluding specified compds.) are prepared Thus,
 N-(5-benzyl-4-phenyl-1,3-thiazol-2-yl)-4-(4-ethoxyphenyl)-4-oxobutanamide was prepared in 3 steps

L6 ANSWER 4 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 from phenetole and succinic anhydride. 19 Compds. of this invention showed IC50 values ≤ 10 nM against diacylglycerol acyltransferase. Formulations are given.
 IT 905589-72-2P 905589-73-3P 905591-16-4P 905591-17-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Preparation of amide compds. as diacylglycerol acyltransferase inhibitors)
 RN 905589-72-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-[(4-ethoxybenzoyl)amino]ethyl]-1-(4-methoxyphenyl)-2-methyl-5-phenyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



L6 ANSWER 4 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 905589-73-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-[(4-ethoxybenzoyl)amino]ethyl]-2-methyl-1-(4-(methylthio)phenyl)-5-phenyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



L6 ANSWER 4 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 905591-17-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-[(4-ethoxybenzoyl)amino]ethyl]-2-methyl-5-phenyl-1-(4-(trifluoromethoxy)phenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 905591-16-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-[(4-ethoxybenzoyl)amino]ethyl]-2-methyl-5-phenyl-1-(4-(trifluoromethoxy)phenyl)- (9CI) (CA INDEX NAME)

10743642

L6 ANSWER 4 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006.677655 CAPLUS

DOCUMENT NUMBER: 145:124571

TITLE: preparation of imidazoles and pyrazoles as CB1 and/or CB2 cannabinoid receptor ligands.

INVENTOR(S): Makriyannis, Alexandros; Thotapally, Rajesh; Vemuri, Venkata Kiran Rao; Olszewska, Teresa

PATENT ASSIGNEE(S): Vemuri, Venkata, Kiran, Rao, USA

SOURCE: PCT Int. Appl., 92 pp.

CODE: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006074445	A2	20060713	WO 2006-US720	20060110
WO 2006074445	A3	20060928		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-642544P P 20050110

OTHER SOURCE(S): MARPAT 145:124571

GI



AB Title compds. e.g. [I; A, B = bond, O, (CH2)1R5; B = bond, O, NRS; R5 = H, (substituted) alkyl; 1 = 0, 1; R1, R2 = (CH2)nZ; n = 0-7; Z = H, halo, N3,

L6 ANSWER 5 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

NCS, cyano, NO2, OAc, acyloxy, aryloxy, acylamino, alkoxy, substituted carbocyclyl, heterocyclyl, etc.; R3 = specified 5-6 membered ring, bicycloheptyl, adamantyl, fused ring system, etc.; R4 = H, halo, N3, NCS, Ph, cyano, NO2, carbocyclyl, heterocyclyl, aryl, heteroaryl; azabicycloheptyl, etc.), were claimed. Thus, title compd. (II) showed

CB1 receptor binding with $K_i = 1.2$ nM.

IT 897924-69-5 897924-74-2 897924-85-5

897924-86-6 897924-87-7 897924-88-8

897924-89-9 897924-90-2 897925-15-4

897925-16-5 897925-18-7 897925-19-8


897925-26-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of imidazoles and pyrazoles as CB1 and/or CB2 cannabinoid receptor ligands)


RN 897924-69-5 CAPLUS

CN 1H-Imidazole-4-carboxamide, 1-(4-bromophenyl)-N-cyclohexyl-2-(2,4-dichlorophenyl)-5-(hydroxymethyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 897924-74-2 CAPLUS

CN 1H-Imidazole-4-carboxamide, N-cyclohexyl-2-(2,4-dichlorophenyl)-5-(hydroxymethyl)-1-(4-iodophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 897924-85-5 CAPLUS

CN 1H-Imidazole-4-carboxamide, N-cyclohexyl-2-(2,4-dichlorophenyl)-N,5-dimethyl-1-[4-(1H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)


SAEED

L6 ANSWER 5 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 897924-86-6 CAPLUS

CN 1H-Imidazole-4-carboxamide, N-cyclohexyl-2-(2,4-dichlorophenyl)-N,5-dimethyl-1-[4-(1-methyl-1H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 897924-87-7 CAPLUS


CN 1H-Imidazole-4-carboxamide, N-cyclohexyl-2-(2,4-dichlorophenyl)-N,5-dimethyl-1-[4-(2-methyl-2H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)

10743642

L6 ANSWER 5 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 897924-88-8 CAPLUS
 CN 1H-Imidazole-4-carboxamide, N-cyclohexyl-2-(2,4-dichlorophenyl)-5-(hydroxymethyl)-N-methyl-1-[4-(1H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 897924-89-9 CAPLUS
 CN 1H-Imidazole-4-carboxamide, N-cyclohexyl-2-(2,4-dichlorophenyl)-5-(hydroxymethyl)-N-methyl-1-[4-(1-methyl-1H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 5 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 897924-90-2 CAPLUS
 CN 1H-Imidazole-4-carboxamide, N-cyclohexyl-2-(2,4-dichlorophenyl)-5-(hydroxymethyl)-N-methyl-1-[4-(2-methyl-2H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 897925-15-4 CAPLUS
 CN 1H-Imidazole-4-carboxamide, N-cyclohexyl-2-(2,4-dichlorophenyl)-1-[4-(4-hydroxy-1-butynyl)phenyl]-N,5-dimethyl- (9CI) (CA INDEX NAME)


L6 ANSWER 5 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 897925-16-5 CAPLUS
 CN 1H-Imidazole-4-carboxamide, N-cyclohexyl-2-(2,4-dichlorophenyl)-1-[4-(3-hydroxy-1-propynyl)phenyl]-N,5-dimethyl- (9CI) (CA INDEX NAME)




RN 897925-18-7 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 1-[4-(3-azido-1-propynyl)phenyl]-N-cyclohexyl-2-(2,4-dichlorophenyl)-N,5-dimethyl- (9CI) (CA INDEX NAME)




RN 897925-19-8 CAPLUS
 CN 1H-Imidazole-4-carboxamide, N-cyclohexyl-2-(2,4-dichlorophenyl)-1-[4-(3-isothiocyanato-1-propynyl)phenyl]-N,5-dimethyl- (9CI) (CA INDEX NAME)

L6 ANSWER 5 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 897925-26-7 CAPLUS
 CN 1H-Imidazole-4-carboxamide, N-cyclohexyl-2-(2,4-dichlorophenyl)-1-[4-(3-hydroxypropyl)phenyl]-N,5-dimethyl- (9CI) (CA INDEX NAME)




SAAED

10743642

L6 ANSWER 6 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:634010 CAPLUS
 DOCUMENT NUMBER: 145:103674
 TITLE: Preparation of 1,2-diarylimidazoles as CBI modulators for treating obesity, psychiatric and neurological disorders
 INVENTOR(S): Cheng, Leifeng
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
 SOURCE: PCT Int. Appl., 57 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006067428	A2	20060629	WO 2005-GB4956	20051221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TO, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLM. INFO.:			GB 2004-28073	A 20041223
			GB 2005-14348	A 20050713

OTHER SOURCE(S): MARPAT 145:103674
 GI




AB The title compds. I [R1 = (un)substituted alkoxy, O(CH2)pPh (p = 1-3), etc.; R2 = halo, alkyl, alkoxy; n = 0-3; R3 = alkyl, alkoxy, OH, NO2, CN or halo; n = 0-3; R4 = XNHR7R8 (X = CO or SO2; Y = absent or

L6 ANSWER 6 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (un)substituted NH; R7, R8 = alkyl, cycloalkyl, cycloalkylalkylene, etc.).
 oxazolyl, thiazolyl, etc.; R4 = alkyl substituted by OH, (un)substituted NH2], useful in the treatment of obesity, psychiatric and neurol. disorders, were prepd. E.g., a multi-step synthesis of
 propane-1-sulfonic acid 4-[(2-(2,4-dichlorophenyl)-5-hydroxymethyl-4-(piperidin-1-yl)carbamoyl)imidazol-1-yl]phenyl ester (II), starting from p-anisidine and
 2,4-dichlorobenzonitrile, was given. Comps. I are active at the CBI receptor (IC50 < 1 μM). Most preferred compds. have IC50 < 200 nM. For example, II showed IC50 of 3 nM. Pharmaceutical compn. contg. compd. I is disclosed.
 IT 895136-60-4P 895136-68-2P 895136-73-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Preparation of diarylimidazoles as CBI modulators for treating obesity, psychiatric and neurol. disorders)
 RN 895136-60-4 CAPLUS
 CN 1-Propanesulfonic acid, 3,3,3-trifluoro-, 4-[(2-(2-cyanophenyl)-5-(hydroxymethyl)-4-[[[1-(hydroxymethyl)-3-methylbutyl]amino]carbonyl]-1H-imidazol-1-yl]phenyl ester (9CI) (CA INDEX NAME)




RN 895136-68-2 CAPLUS
 CN 1-Propanesulfonic acid, 3,3,3-trifluoro-, 4-[(2-(2-chlorophenyl)-4-[[[1,4-dimethylpentyl]amino]carbonyl]-5-(hydroxymethyl)-1H-imidazol-1-yl]phenyl ester (9CI) (CA INDEX NAME)


L6 ANSWER 6 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 895136-73-9 CAPLUS
 CN 1-Butanesulfonic acid, 4,4,4-trifluoro-, 4-[(2-(3-cyano-5-fluorophenyl)-4-[[[1-ethylbutyl]amino]carbonyl]-5-(hydroxymethyl)-1H-imidazol-1-yl]phenyl ester (9CI) (CA INDEX NAME)




L6 ANSWER 7 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:456735 CAPLUS
 DOCUMENT NUMBER: 145:145480
 TITLE: Solution Phase Synthesis of a Library of Tetrasubstituted Pyrrole Amides
 AUTHOR(S): Bianchi, Ivana; Forlani, Roberto; Minetto, Giacomo; Peretto, Iaria; Regalia, Nickolas; Taddei, Maurizio; Ravaglia, Luca P.
 CORPORATE SOURCE: NIKem Research, Baranzate, Milan, 20021, Italy
 SOURCE: Journal of Combinatorial Chemistry (2006), 8(4), 491-499
 CODEN: JCCHFF; ISSN: 1520-4766
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB An efficient strategy for the solution-phase parallel synthesis of a library of pyrrole amides is described. Key reactions include functional homologation of β-ketoesters with a set of aldehydes followed by oxidation to produce a series of differently substituted 1,4-dicarbonyl compds. Rapid cyclization using a microwave-assisted Paal-Knorr reaction provided a set of 24 pyrrole esters that were further functionalized through a trimethylaluminum-mediated aminolysis to obtain a larger library of 288 diverse pyrrole-3-amides. The tetrasubstitution allows a good exploration of the chemical space around the central pyrrole core. The last step was entirely automated with a Bohdan Myriad personal synthesizer.
 IT 898222-10-1P 898222-12-3P
 RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
 (solution-phase parallel synthesis of a library of pyrrole amides via homologation of β-ketoesters with aldehydes, oxidation, microwave-assisted Paal-Knorr cyclocondensation with amines, and trimethylaluminum-mediated aminolysis)
 RN 898222-10-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-(2-furanylmethyl)-5-phenyl-1-(2-phenylethyl)-2-propyl- (9CI) (CA INDEX NAME)



RN 898222-12-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-phenyl-1-(2-phenylethyl)-2-(phenylmethyl)-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)

10743642

L6 ANSWER 7 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L6 ANSWER 8 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:411734 CAPLUS
 DOCUMENT NUMBER: 144:456511
 TITLE: Pharmaceutical compositions comprising CBI receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type I, obesity and related conditions
 INVENTOR(S): Firnges, Michael; Gregory, Peter-Colin; Antel, Jochen;
 PATENT ASSIGNEE(S): Lange, Josephus Hubertus Maria; Waldeck, Harald
 SOURCE: Solvay Pharmaceuticals GmbH, Germany
 PCT Int. Appl., 51 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006045799	A2	20060504	WO 2005-EP55534	20051025
WO 2006045799	A3	20060727		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KH, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, ME, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SN, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BO, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006128673	A1	20060615	US 2005-257056	20051025
PRIORITY APPLN. INFO.: EP 2004-105265 A 20041025				
US 2004-621077P P 20041025				
US 2005-651625P P 20050211				


OTHER SOURCE(S): MARPAT 144:456511
 AB Described is a novel combination therapy for diabetes mellitus type I and/or for obesity and its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, by administering a combination of at least one KATP channel opener as a first active agent and at least one CBI cannabinoid receptor antagonist as a second active agent. The invention is further directed to such novel combination therapy wherein a dually acting compound with combined KATP channel opening and CBI antagonistic properties is used. The invention also relates to novel pharmaceutical compns. comprising KATP channel openers and CBI antagonists and the use of said pharmaceutical compns. in the treatment, delayed progression, delayed

L6 ANSWER 8 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 onset of and/or inhibition of diabetes mellitus type I, and the prophylaxis and treatment, of obesity as well as the prophylaxis, treatment, delayed onset and/or inhibition of its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, in mammals and humans. The invention is further directed to such novel pharmaceutical compns. comprising a dually acting compd. with combined KATP channel opening and CBI antagonistic properties. The test confirms the lack of agonist effect and the potency of the candidate com-pounds to inhibit glucose-stimulated insulin release and thus their potential to preserve pancreatic beta cell function and to prevent or delay the progression of diabetes. Thus, (4S)-3-(4-chlorophenyl)-N'-[(4-chlorophenyl)sulfonyl]-N-methyl-4-25-phenyl-4,5-dihydro-1-H-pyrazole-1-carboximidamide (I) produced a sustained non-dose-dependent redn. in rats body wt. at all doses administered. Capsules contained 150, corn starch 150, lactose 150, talc 15, magnesium stearate 15, and corn starch 20 mg.
 IT 505073-48-3, 1-(4-Bromophenyl)-2-(2,4-dichlorophenyl)-5-ethyl-N-pentyl-1H-imidazole-4-carboxamide 505073-66-5, 1-(4-Chlorophenyl)-2-(2,4-dichlorophenyl)-N,N-diethyl-1H-imidazole-4-carboxamide 505074-51-1
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical compns. comprising CBI receptor antagonists and potassium channel openers for treatment of diabetes mellitus type I, obesity and related conditions)
 RN 505073-48-3 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-5-ethyl-N-pentyl- (9CI) (CA INDEX NAME)




RN 505073-66-5 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N,N-diethyl- (9CI) (CA INDEX NAME)

L6 ANSWER 8 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 505074-51-1 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-N-[(4-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)



SAEED

10743642

L6 ANSWER 9 OF 43 CAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 2006:33235 CAPLUS

DOCUMENT NUMBER: 144:35059

TITLE: Preparation of pyrrolecarboxamide derivatives as mineralocorticoid receptor antagonists for use

against

INVENTOR(S): cancer and other disorders
 Canne Bannen, Lynne; Chen, Jeff; Dalrymple, Lisa
 Eather, Platt, Brenton T.; Forsyth, Timothy Patrick;
 Gu, Xiao-Hu; Mac, Morrison B.; Mann, Larry W.; Mann,
 Grace; Martin, Richard; Mohan, Raju; Murphy, Brett;
 Nymann, Michael Charles; Stevens, William C., Jr.;
 Wang, Tie-Lin; Wong, Yong; Wu, Jason H.

PATENT ASSIGNEE(S): Exelixa, Inc., USA

SOURCE: PCT Int. Appl., 477 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006012642	A2	20060202	WO 2005-US26916	20050730
WO 2006012642	A3	20060727		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM


PRIORITY APPLN. INFO.: US 2004-592439P P 20040730
 US 2004-592469P P 20040730

OTHER SOURCE(S): MARPAT 144:350539

GI



L6 ANSWER 9 OF 43 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



L6 ANSWER 9 OF 43 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

AB Pyrrolecarboxamide derivs. (shown as I; other Markush structures for pyrrolecarboxamides are defined in the claims; variables defined below; e.g. 1-[4-fluoro-2-(trifluoromethyl)phenyl]-2,5-dimethyl-1H-pyrrole-3-carboxylic acid N-[4-(sulfamoyl)phenyl]amide (II)), compns. and methods for modulating the activity of receptors are provided. In particular compds. and compns. are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of 21 symptoms of disease or disorder directly or indirectly related to the activity of the receptors. Semiquant. IC50 values for antagonist activity of 23 examples of I are tabulated and compared to the activity of the spironolactone control. For I: R1 and R2 = H, halo, cyano, or (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, or heterocyclylalkyl, or -OR9, -SR9, -N(R9)2, -C(O)OR9 or -C(O)N(R9)2; R3 = H, halo, cyano, (un)substituted alkyl, (un)substituted alkenyl or (un)substituted alkynyl; R4 is H, -C(O)R9, -S(O)2R9, or (un)substituted alkyl, alkenyl or alkynyl, or R4 is (un)substituted cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl; R6 is H or (un)substituted alkyl; R7 is (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl; addnl. details are given in the claims. Although the methods of preparation are not claimed, preps. and/or characterization

data for many examples of I are included. For example, II was prepared in 5 steps (50, 37, 62, 64, and 66 % yields, resp.) starting with preparation

of 1-[4-fluoro-2-(trifluoromethyl)phenyl]-2,5-dimethyl-1H-pyrrole from 4-fluoro-2-(trifluoromethyl)aniline and 2,5-hexanedione, followed by preparation of the following intermediates: 1-[4-fluoro-2-(trifluoromethyl)phenyl]-2,5-dimethyl-1H-pyrrole-3-carboxaldehyde, 1-[4-fluoro-2-(trifluoromethyl)phenyl]-2,5-dimethyl-1H-pyrrole-3-carboxylic acid, and 1-[4-fluoro-2-(trifluoromethyl)phenyl]-2,5-dimethyl-1H-pyrrole-3-carbonyl chloride and finally amide formation with sulfamylamide.

IT 880779-33-9P, 5-[4-Fluorophenyl]-2-methyl-1-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxylic acid dimethylamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrrolecarboxamide derivs. as mineralocorticoid receptor antagonists for use against cancer and

other disorders)

RN 880779-33-9 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-(4-fluorophenyl)-N,N,2-trimethyl-1-[2-(trifluoromethyl)phenyl]- (9C1) (CA INDEX NAME)

L6 ANSWER 10 OF 43 CAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 2005:1354478 CAPLUS

DOCUMENT NUMBER: 144:88561

TITLE: Preparation of amino acid heterocyclic derivatives for

treatment of hyperlipidemia and related diseases

INVENTOR(S): Sircar, Jagadish C.; Thomas, Richard J.; Khatuya,

Haripada; Nikoulin, Igor

PATENT ASSIGNEE(S): Avanir Pharmaceuticals, USA

SOURCE: PCT Int. Appl., 106 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005123686	A1	20051229	WO 2005-US20660	20050609

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2006009487 A1 20060112 US 2005-149067 20050609
 PRIORITY APPLN. INFO.: US 2004-578227P P 20040609

GI



AB The invention provides compns. adapted to enhance reverse cholesterol transport in mammals and which are suitable for oral delivery and useful in the treatment and/or prevention of hypercholesterolemia, atherosclerosis and associated cardiovascular diseases. Mediators of reverse cholesterol transport comprise a structure having components A, B and C, where A comprises an acidic moiety having an acidic group or a bioisostere, B comprises an aromatic or lipophilic moiety having at least a


SAAED

10743642


L6 ANSWER 10 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 portion of HMGCoA reductase inhibitor or an analog, and C comprises a
 basic moiety having a basic group or bioisostere. An example describes
 the synthesis of lipophilic group-modified peptide sequence I.TFA based

on atorvastatin.
 IT 872406-24-1P 872406-25-2P 872406-26-3P
 872406-27-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of amino acid heterocyclic derivs. for treatment of
 hyperlipidemia and related diseases)
 RN 872406-24-1 CAPLUS
 CN Pentanoic acid, 4-[[[4-[[[2-(acetylamino)-5-[(aminoininomethyl)amino]-1-
 oxopentyl]amino]-2-methyl-1,5-diphenyl-1H-pyrrol-3-yl]carbonyl]amino]-5-
 amino-5-oxo- (9CI) (CA INDEX NAME)




RN 872406-25-2 CAPLUS
 CN Butanoic acid, 4-[[[4-[[[5-[(aminoininomethyl)amino]-1-oxopentyl]amino]-2-
 methyl-1,5-diphenyl-1H-pyrrol-3-yl]carbonyl]amino]-5-oxo- (9CI) (CA INDEX
 NAME)




RN 872406-26-3 CAPLUS
 CN Pentanoic acid, 4-[(acetylamino)-5-[[[4-[[[1-(aminocarbonyl)-4-
 [(aminoininomethyl)amino]butyl]amino]carbonyl]-5-methyl-1,2-diphenyl-1H-
 pyrrol-3-yl]amino]-5-oxo- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 872406-27-4 CAPLUS
 CN Pentanoic acid,
 5-[[[4-[[[4-[(aminoininomethyl)amino]butyl]amino]carbonyl]-
 5-methyl-1,2-diphenyl-1H-pyrrol-3-yl]amino]-5-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L6 ANSWER 11 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1154377 CAPLUS
 DOCUMENT NUMBER: 143:422349
 TITLE: Preparation of imidazole derivatives for promoting
 smoking cessation
 INVENTOR(S): Gardell, Stephen J.
 PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
 SOURCE: PCT Int. Appl., 176 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005099705	A2	20051027	WO 2005-US8904	20050318
WO 2005099705	A3	20060119		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
 SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
 ZW


RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-555920P P 20040324

OTHER SOURCE(S): MARPAT 143:422349
 GI



II




AB The title compds. I [R1, R2 = (un)substituted Ph, alkyl, (un)substituted
 cyclohexyl, etc.; R3 = H, alkyl, CH2Ph, Cl, Br; X = CONR4R5 (wherein R4 =
 H, alkyl; R5 = (un)substituted alkyl, bicycloalkyl, CH2Ph, etc.; or NR4R5
 = (un)substituted 5-10 membered (un)saturated heterocyclyl], CONHSO2R10
 (R10 =

SAEED

L6 ANSWER 11 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

(un)substituted alkyl, Ph, benzocyclohexyl, benzocyclopentyl] which are
 useful in promoting smoking cessation and maintaining abstinence, were
 prepd. E.g. a 2-step synthesis of II, starting from 2-chloro-N-(4-
 chlorophenyl)benzenecarboximidamide and Et 3-bromo-2-oxopentanoate, was
 given. The pharmaceutical compns. comprising the compd. I in combination
 with one or more nicotine replacement therapies or one of more nicotinic
 receptor modulators are disclosed.


IT 527369-03-SP
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of imidazole derivs. for promoting smoking cessation)
 RN 527369-03-5 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 2-(2-chlorophenyl)-1-(4-chlorophenyl)-N-
 methoxy-N-methyl- (9CI) (CA INDEX NAME)




IT 527367-84-6P 527368-19-0P 527368-57-6P
 527368-66-7P 527368-71-4P 527370-18-9P
 527370-23-6P 527370-28-1P 527370-33-8P
 527370-47-4P 527370-52-1P 527370-68-9P
 527370-73-6P 527370-77-0P 527370-82-7P
 527370-87-2P 527371-19-3P 527371-24-0P
 527371-53-5P 527375-14-0P 527375-87-7P
 527375-90-2P 527375-94-6P 527375-99-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of imidazole derivs. for promoting smoking cessation)
 RN 527367-84-6 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 2-(2-chlorophenyl)-1-(4-chlorophenyl)-N-
 cyclohexyl-N-methyl- (9CI) (CA INDEX NAME)

10743642

L6 ANSWER 11 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 527368-19-0 CAPLUS
 CN 1H-Imidazole-4-carboxamide,
 2-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N,N-
 dimethyl- (9CI) (CA INDEX NAME)




RN 527368-57-6 CAPLUS
 CN 1H-Imidazole-4-carboxamide,
 2-(2-chlorophenyl)-1-(4-chlorophenyl)-N-methyl-
 N-(1-methyl-3-pyrrolidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 11 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● HCl

RN 527370-18-9 CAPLUS
 CN 1H-Imidazole-4-carboxamide,
 2-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-[2-
 (1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 527370-23-6 CAPLUS
 CN 1H-Imidazole-4-carboxamide,
 2-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-[2-
 (diethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 527370-28-1 CAPLUS

SAEED


L6 ANSWER 11 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl

RN 527368-66-7 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-
 methyl-N-[(1R,2R)-2-(methylamino)cyclohexyl]-, monohydrochloride (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 527368-71-4 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-
 methyl-N-[(1S,2S)-2-(methylamino)cyclohexyl]-, monohydrochloride (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.

L6 ANSWER 11 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 527370-33-8 CAPLUS
 CN 1H-Imidazole-4-carboxamide,
 2-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-[2-
 (dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 527370-33-8 CAPLUS
 CN 1H-Imidazole-4-carboxamide,
 2-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-[2-
 (dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 527370-47-4 CAPLUS
 CN 1H-Imidazole-4-carboxamide,
 2-(2-chlorophenyl)-1-(4-chlorophenyl)-N-propyl-
 (9CI) (CA INDEX NAME)




10743642

L6 ANSWER 11 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 527370-52-1 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 2-(2-chlorophenyl)-1-(4-chlorophenyl)-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 527370-68-9 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 2-(2-chlorophenyl)-1-(4-chlorophenyl)-N-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 527370-73-6 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 2-(2-chlorophenyl)-1-(4-chlorophenyl)-N-[(2,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 11 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 527370-87-2 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 1-(4-chlorophenyl)-N-[[3-(1-pyrrolidinyl)propyl]-2-(2-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 527371-19-3 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 2-(2,4-dichlorophenyl)-N-[[{(1R,2R)-2-hydroxycycloheptyl)methyl]-1-(4-methoxyphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




SAEED

L6 ANSWER 11 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 527370-77-0 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 2-(2-chlorophenyl)-1-(4-chlorophenyl)-N-[[3-(1-pyrrolidinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



• HCl


RN 527370-82-7 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-[[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




L6 ANSWER 11 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 527371-24-0 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 2-(2,4-dichlorophenyl)-N-[[{(1R,2S)-2-hydroxycyclohexyl)methyl]-1-(4-methoxyphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 527371-53-5 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 2-(2-chlorophenyl)-1-(4-chlorophenyl)-N-[[1-ethyl-2-pyrrolidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




• HCl

RN 527375-14-0 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 2-(2-chlorophenyl)-1-(4-chlorophenyl)-N-[[2-(4-dimethoxyphenyl)methyl]-N-[(2R,3R)-1,2,3,4-tetrahydro-3-hydroxy-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10743642

L6 ANSWER 11 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 527375-87-7 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 2-(2,4-dichlorophenyl)-N-[(1R)-2-hydroxy-1-phenylethyl]-1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 527375-90-2 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 2-(2,4-dichlorophenyl)-N-[(1S)-2-hydroxy-1-phenylethyl]-1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 11 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




L6 ANSWER 11 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 527375-94-6 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 2-(2-chlorophenyl)-1-(4-chlorophenyl)-N-[(1R)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 527375-99-1 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 2-(2-chlorophenyl)-1-(4-chlorophenyl)-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L6 ANSWER 12 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:1026892 CAPLUS
 DOCUMENT NUMBER: 143:326363
 TITLE: Preparation of substituted imidazoles as calcium ion channel modulators
 INVENTOR(S): Zelle, Robert; Galullo, Vincent P.
 PATENT ASSIGNEE(S): Scion Pharmaceuticals, Inc., USA; Wyeth
 SOURCE: PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005086902	A2	20050922	WO 2005-US7913	20050307
WO 2005086902	A3	20060706		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MN, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005221138	A1	20050922	AU 2005-221138	20050307
CA 2557650	A1	20050922	CA 2005-2557650	20050307
EP 1722786	A2	20061122	EP 2005-725219	20050307
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
PRIORITY APPLN. INFO.:			US 2004-551394P	P 20040308
			WO 2005-US7913	W 20050307

OTHER SOURCE(S): MARPAT 143:326363
 GI




AB The title imidazoles I [Ar1 = (un)substituted cycloalkyl, aryl, heterocyclyl or heteroaryl; R1 = Ar2, alkyl optionally substituted with

SAAED

10743642



L6 ANSWER 12 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Ar2 (wherein Ar2 = (un)substituted cycloalkyl, aryl, heterocyclyl or heteroaryl); R2 = CO2R3, COAr3, CONR3R4, Ar3, CH2NR3R4; (R3 = H, alkyl;
R4 = H, alkyl, CO2R5, etc.; R5 = H, alkyl, haloalkyl, etc.; Ar3 = (un)substituted cycloalkyl, aryl, heterocyclyl or heteroaryl) which can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel subtype targets, were claimed. E.g., a 2-step synthesis of II, starting from Et 2-(2-methoxyphenyl)-1-p-tolyl-1H-imidazole-4-carboxylate (prepn. given), was given. Oocyte assays, HEX assays, and formalin tests were carried out (data given for representative compds. I).
IT 865079-40-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted imidazoles as calcium ion channel modulators)
RN 865079-40-9 CAPLUS
CN 1H-imidazole-4-carboxamide, N-methoxy-2-(2-methoxyphenyl)-N-methyl-1-(4-methylphenyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 13 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1026876 CAPLUS
DOCUMENT NUMBER: 143:326362
TITLE: Preparation of substituted imidazoles as calcium ion channel modulators
INVENTOR(S): Zelle, Robert; Galullo, Vincent P.; Baker, Christopher
PATENT ASSIGNEE(S): Todd; Will, Paul; Frazee, William J.; Mazdiyasni, Hormoz; Guo, Jinsong
SOURCE: Scion Pharmaceuticals, Inc., USA
PCT Int. Appl., 430 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005086836	A2	20050922	WO 2005-US7667	20050307
WO 2005086836	A3	20060105		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005220911	A1	20050922	AU 2005-220911	20050307
CA 2557637	A1	20050922	CA 2005-2557637	20050307
EP 1723117	A2	20061122	EP 2005-725050	20050307
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.: US 2004-551372P P 20040308				
US 2004-551395P P 20040308				
US 2004-551472P P 20040308				
US 2004-551473P P 20040308				
US 2004-551474P P 20040308				
US 2004-551480P P 20040308				
US 2004-551503P P 20040308				
US 2004-551510P P 20040308				
US 2004-551620P P 20040308				

L6 ANSWER 13 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
WO 2005-US7667 W 20050307
OTHER SOURCE(S): MARPAT 143:326362
GI



AB The title imidazoles such as I (Ar1 = (un)substituted cycloalkyl, aryl, heterocyclyl or heteroaryl; X = NR3, C(R3)2, O; Y = C(O), alkylene; R1 = Ar2, alkyl optionally substituted with Ar2 (wherein Ar2 = (un)substituted cycloalkyl, aryl, heterocyclyl or heteroaryl); q = 0-2; R2 = (CH2)mCO2R3, (CH2)mCOAr3, (CH2)mAr3, etc. (R3 = H, alkyl; m = 1-2; Ar3 = (un)substituted cycloalkyl, aryl, heterocyclyl or heteroaryl) which can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel subtype targets, were prepared E.g., a multi-step synthesis of II, starting from p-toluidine, was given. Oocyte assays, HEX assays, and formalin tests were carried out (no data given).
IT 865079-40-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted imidazoles as calcium ion channel modulators)
RN 865079-40-9 CAPLUS
CN 1H-imidazole-4-carboxamide, N-methoxy-2-(2-methoxyphenyl)-N-methyl-1-(4-methylphenyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 13 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



SAEED


10743642

L6 ANSWER 14 OF 43 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 2005:220141 CAPLUS
 DOCUMENT NUMBER: 142:280212
 TITLE: Preparation of 1H-imidazole-4-carboxamides as CB1 agonists, partial agonists, or antagonists for treatment of psychiatric and neurological disorders
 INVENTOR(S): Kruse, Cornelis G.; Lange, Josephus H. M.; Herremans, Arnoldus H. J.; Van Stuijvenberg, Herman H.
 PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V., Neth.
 SOURCE: U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U.S. Ser. No. 490,019.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005054679	A1	20050310	US 2004-912171	20040806
US 7109216	B2	20060919		
WO 2003027076	A2	20030403	WO 2002-EP10434	20020917
WO 2003027076	A3	20031120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004235854	A1	20041125	US 2004-490019	20040319
US 2005267161	A1	20051201	US 2005-138289	20050527
PRIORITY APPLN. INFO.: EP 2001-203851 A 20010921				
WO 2002-EP10434 W 20020917				
US 2004-490019 A2 20040319				
US 2004-574939P P 20040528				


OTHER SOURCE(S): CASREACT 142:280212; MARPAT 142:280212
 GI

L6 ANSWER 14 OF 43 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
 dichlorophenyl)-N,N,5-trimethyl-1H-imidazole-4-carboxamide
 505074-05-SP, 1-(4-Chlorophenyl)-2-(2-methoxy-4-chlorophenyl)-5-methyl-N-pentyl-1H-imidazole-4-carboxamide 505074-13-SP,
 1-(4-Chlorophenyl)-2-(2-fluoro-4-chlorophenyl)-5-methyl-N-pentyl-1H-imidazole-4-carboxamide 505074-18-OP, 2-(2-Chlorophenyl)-1-(3-fluorophenyl)-5-methyl-N-pentyl-1H-imidazole-4-carboxamide
 505074-21-SP, 2-(2-Chlorophenyl)-1-(3-fluorophenyl)-N-(2-(4-fluorophenyl)ethyl)-5-methyl-1H-imidazole-4-carboxamide
 505074-32-SP, 1-(4-Chlorophenyl)-2-(2,4-dichlorophenyl)-N-(2-fluoroethyl)-5-methyl-1H-imidazole-4-carboxamide 505074-36-2P,
 1-(4-Chlorophenyl)-2-(2,4-dichlorophenyl)-N-(4-fluorobenzyl)-5-methyl-1H-imidazole-4-carboxamide 505074-50-OP, 1-(4-Chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-N-[3-(trifluoromethyl)benzyl]-1H-imidazole-4-carboxamide 505074-51-1P, 1-(4-Chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-N-[4-(trifluoromethyl)benzyl]-1H-imidazole-4-carboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (CB1 modulator; prepn. of imidazolecarboxamides as CB1 agonists, partial agonists, or antagonists for treatment of psychiatric and neurol. disorders)
 RN 505073-32-5 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 505073-48-3 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-5-ethyl-N-pentyl- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 43 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




AB Title compds. I [wherein R = (un)substituted Ph, thienyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, or triazinyl; R1 = (un)substituted Ph
 or pyridinyl; R2 = H or (cyclo)alkyl or (cyclo)alkenyl optionally interrupted by S, O, or N; R3 = (un)substituted (cyclo)alkyl, (cyclo)alkoxy, bicycloalkyl, tricycloalkyl, or (cyclo)alkenyl optionally interrupted by N, O, or S; or R3 = pyridinyl or Ph when R4 = H; or R3 = NR5R6 when R2 = H or Me; or NR2R3 = (un)substituted heterocyclyl; R4 = H, halo, CN, carbamoyl, formyl, acetyl, CF3CO, FCH2CO, EtCO, sulfonyl, MesO2, MeS, or (un)substituted alkyl; R5 and R6 = independently alkyl; or NR5R6 = (un)substituted heterocyclyl; and prodrugs, stereoisomers, and salts thereof] were prepared as potent cannabinoid (CB1) receptor agonists, partial agonists, or antagonists. For example, reaction of 4-chloroaniline with 2,4-dichlorobenzonitrile in the presence of sodium bis(trimethylsilyl)amide in THF provided N-(4-chlorophenyl)-2,4-dichlorobenzene-carboxamide (42%). Cyclization of the carboxamide with Et 3-bromo-2-oxopropenoate in a solution of NaHCO3 and isopropanol gave the imidazolecarboxylate (29%), which was converted to the imidazolecarbonyl chloride (no data). Amidation with 1-aminopiperidine using TEA in CH2Cl2 afforded II (26%). Selected I bound to hCB1 receptor with pKi values in the range of 7.0 to 8.4. I are useful for the treatment of psychiatric and neurol. disorders, as well as and other diseases involving cannabinoid neurotransmission (no data).
 IT 505073-32-5P, N-(Benzyl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-methyl-1H-imidazole-4-carboxamide 505073-48-3P, 1-(4-Bromophenyl)-2-(2,4-dichlorophenyl)-5-ethyl-N-pentyl-1H-imidazole-4-carboxamide 505073-56-3P, 1-(4-Chlorophenyl)-2-(2,4-dichlorophenyl)-N-(4-fluorobenzyl)-1H-imidazole-4-carboxamide 505073-63-2P, 1-(4-Chlorophenyl)-2-(2-methoxy-4-chlorophenyl)-N-pentyl-1H-imidazole-4-carboxamide 505073-66-5P, 1-(4-Chlorophenyl)-2-(2,4-dichlorophenyl)-N,N-diethyl-1H-imidazole-4-carboxamide 505073-71-2P, 1-(4-Chlorophenyl)-N-(2,2,2-trifluoroethyl)-2-(2-trifluoromethyl-4-chlorophenyl)-1H-imidazole-4-carboxamide 505073-89-2P, 1-(4-Chlorophenyl)-2-(2,4-


L6 ANSWER 14 OF 43 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 505073-56-3 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)





RN 505073-63-2 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 2-(4-chloro-2-methoxyphenyl)-1-(4-chlorophenyl)-N-pentyl- (9CI) (CA INDEX NAME)





RN 505073-66-5 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N,N-

SAEED




10743642

L6 ANSWER 14 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
diethyl- (9CI) (CA INDEX NAME)RN 505073-71-2 CAPLUS
CN 1H-imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-([4-chloro-2-(trifluoromethyl)phenyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)RN 505074-89-2 CAPLUS
CN 1H-imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N,N,5-trimethyl- (9CI) (CA INDEX NAME)




L6 ANSWER 14 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 505074-05-5 CAPLUS
CN 1H-imidazole-4-carboxamide, 2-(4-chloro-2-methoxyphenyl)-1-(4-chlorophenyl)-5-methyl-N-pentyl- (9CI) (CA INDEX NAME)RN 505074-13-5 CAPLUS
CN 1H-imidazole-4-carboxamide, 2-(4-chloro-2-fluorophenyl)-1-(4-chlorophenyl)-5-methyl-N-pentyl- (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 505074-18-0 CAPLUS
CN 1H-imidazole-4-carboxamide, 2-(2-chlorophenyl)-1-(3-fluorophenyl)-5-methyl-N-pentyl- (9CI) (CA INDEX NAME)RN 505074-21-5 CAPLUS
CN 1H-imidazole-4-carboxamide, 2-(2-chlorophenyl)-1-(3-fluorophenyl)-5-methyl-N-pentyl- (9CI) (CA INDEX NAME)RN 505074-32-8 CAPLUS
CN 1H-imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-(2-fluoroethyl)-5-methyl- (9CI) (CA INDEX NAME)


L6 ANSWER 14 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 505074-36-2 CAPLUS
CN 1H-imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-[(4-fluorophenyl)methyl]-5-methyl- (9CI) (CA INDEX NAME)RN 505074-50-0 CAPLUS
CN 1H-imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-N-[(3-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)RN 505074-51-1 CAPLUS
CN 1H-imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-N-[(4-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)


SAEED

10743642

L6 ANSWER 14 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




L6 ANSWER 15 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:164961 CAPLUS
 DOCUMENT NUMBER: 142:411290
 TITLE: Synthesis, Structure-Activity Relationships at the GABAA Receptor in Rat Brain, and Differential Electrophysiological Profile at the Recombinant Human GABAA Receptor of a Series of Substituted 1,2-Diphenylimidazoles
 AUTHOR(S): Asproni, Battistina; Talani, Giuseppe; Busonero, Fabio; Pau, Amedeo; Sanna, Sebastiano; Cerri, Riccardo; Mascia, Maria Paola; Sanna, Enrico; Biggio, Giovanni
 CORPORATE SOURCE: Dipartimento Farmaco Chimico Tossicologico, Universita
 SOURCE: di Sassari, Sassari, Italy
 Journal of Medicinal Chemistry (2005), 48(7), 2638-2645
 CODEN: JMHMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 142:411290
 GI



AB A series of new 1,2-diphenylimidazole deriva. I (R = H, Me, CO2H, CO2Me, CO2Et, CO2Pr, CONEt2, etc.; X = H, F, Cl, Br, iodo, Me, OMe, NO2, NH2, NHAc; X1 = H, 3-Cl, 4-Cl, 4-F, 3,4-Cl2, 2,4-Cl2) were synthesized and evaluated for their ability to potentiate γ -aminobutyric acid (GABA)-evoked currents in *Xenopus laevis* oocytes expressing recombinant human GABAA receptors. Many of these compds. enhanced GABA action with potencies (EC50 = 0.19-19 μ M) and efficacies (maximal efficacies of up to 640%) similar to or greater than those of anesthetics such as etomidate, propofol, and alphaxalone. Structure-activity relationship anal. revealed that the presence of an ester moiety in the imidazole ring was required for full agonist properties, while modifications made in the Ph rings affected potency and efficacy, with II (X = Br) showing the highest potency. These compds. potentiated the [3H]GABA binding to rat brain membranes, suggesting a site of interaction different from that of GABA. As for etomidate, mutation of asparagine-265 in the β 2 subunit of the GABAA receptor into serine reduced the ability of derivative II (X =

L6 ANSWER 15 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 C1) to modulate the GABA function.
 IT 850339-40-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and GABA-A receptor binding structure-activity of substituted diphenylimidazoles)
 RN 850339-40-1 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 2-(4-bromophenyl)-1-(2,4-dichlorophenyl)-N,N-diethyl- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L6 ANSWER 16 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:996115 CAPLUS
 DOCUMENT NUMBER: 141:410930
 TITLE: Preparation of imidazole derivatives as cyclooxygenase (COX) inhibitors
 INVENTOR(S): Takahashi, Fumie; Terasaka, Tadaashi; Morita, Masataka;
 Konishi, Nobukiyo; Nakamura, Katsumi
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 71 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004099130	A2	20041118	WO 2004-JP5987	20040426
WO 2004099130	A3	20050127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2524889	A1	20041118	CA 2004-2524889	20040426
EP 1620406	A2	20060201	EP 2004-729517	20040426
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,				
HR				
CN 1784386	A	20060607	CN 2004-80012372	20040426
JP 2006525320	T	20061109	JP 2006-507723	20040426
PRIORITY APPLN. INFO.:				
			AU 2003-902208	A 20030508
			AU 2003-903861	A 20030724
			AU 2003-904068	A 20030801
			WO 2004-JP5987	W 20040426
OTHER SOURCE(S): MARPAT 141:410930				
GI				

10743642

L6 ANSWER 16 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB Title compds. I [wherein R1 = (un)substituted (cyclo)alkyl, carbamoyl, cyano, formyl, carboxy or carbonyl; R2 = hydroxy, halo, cyano, or alkoxy; R3 = alkoxy or amino; X, Y = CH or N; et al., or pharmaceutically acceptable salts thereof], were prepared as cyclooxygenase (COX) inhibitors.

E.g., addition reaction of p-anisidine with 6-methoxy-3-pyridinecarbonitrile using NaHMS as base (58.4%) followed by cyclization with 3-bromo-1,1,1-trifluoro-2-propanone (21.5%) gave imidazole II. Tested compds. I, including II, showed effective analgesic activity (coefficient >1.5)


on adjuvant arthritis at a dose of 3.2 mg/kg, and selectively inhibited COX-1 with IC50 (μM) of <0.01 against COX-1 (vs. 2.01 against COX-2). I are therefore useful for the treatment and/or prevention of the diseases associated with COX, such as inflammation, pain, collagen, autoimmune, immunity, thrombosis, cancer and neurodegenerative diseases.

IT 726196-53-8P 726196-55-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(COX inhibitor; preparation of imidazoles as cyclooxygenase (COX) inhibitors)


RN 726196-53-8 CAPLUS
CN 1H-Imidazole-4-carboxamide, N-ethyl-2-(4-methoxyphenyl)-N-methyl-1-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 16 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 792930-95-1 CAPLUS
CN 1H-Imidazole-4-carboxamide, N-ethyl-1,2-bis(4-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)




L6 ANSWER 16 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 726196-55-0 CAPLUS
CN 1H-Imidazole-4-carboxamide, N,N-diethyl-2-(4-methoxyphenyl)-1-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



IT 726196-54-9P 726196-56-1P 792930-95-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(COX inhibitor; preparation of imidazoles as cyclooxygenase (COX) inhibitors)

RN 726196-54-9 CAPLUS
CN 1H-Imidazole-4-carboxamide, N-ethyl-1-(4-hydroxyphenyl)-2-(4-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 726196-56-1 CAPLUS
CN 1H-Imidazole-4-carboxamide, N,N-diethyl-1-(4-hydroxyphenyl)-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 17 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:963181 CAPLUS
DOCUMENT NUMBER: 141:379941
TITLE: Preparation of quinazoline-2,4-diamines as melanin concentrating hormone (MCH) receptor antagonists
INVENTOR(S): Sekiguchi, Yoshikatsu; Kanuma, Yukihiro; Omdera, Katsunori; Tran, Thuy-ahn; Kramer, Bryan Aubrey; Beeley, Nigel Robert Arnold
PATENT ASSIGNEE(S): Taiho Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 988 pp.
CODEN: JKOXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004315511	A	20041111	JP 2004-95046	20040329
PRIORITY APPLN. INFO.:			JP 2003-93418	A 20030331

OTHER SOURCE(S): MARPAT 141:379941
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. Q-L-Y-R1 [Q = Q1, H2N:(NH); wherein R2 = NNNH2, NNNHBoc, (un)substituted NH2, morpholino, 4-acetyl-piperazinyl, 4-phenylpiperazinyl; R1 = each (un)substituted C1-16 alkyl, C2-8 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C3-6 cycloalkenyl, carbocyclic,

alkyl, or heterocyclic; L = each Q2-Q6 or its cis- or trans-isomer, Q7-Q16; R4 = H, C1-3 alkyl; R5 = H, each (un)substituted carbocyclic aryl or C1-3 alkyl; Y = SO2, CO, a single bond, CH2] or salts thereof are prepared. These compds. are MCH receptor antagonists and used for regulating

orphan G protein-coupled receptor SLC-1 and for the prevention and/or treatment of obesity, obesity-related diseases, anxiety, or depression. Thus, hydrolysis of benzyl cis-[(4-(4-dimethylaminoquinazolin-2-ylamino)cyclohexyl)methyl]carbamate over 5% Pd-C in MeOH at 50° under H atmospheric for 3 days gave a solution of

cis-[(4-(4-dimethylaminoquinazolin-2-ylamino)cyclohexyl)methyl]amine in MeOH which underwent reductive alkylation with 4-bromo-2-trifluoromethoxybenzaldehyde and NaBH(OAc)3 in AcOH/CH2Cl2 to give, after purification using HPLC and treatment with 4 N HCl/EtOAc, compound (1). 2HCl. In a high throughput function screen for identifying lead compds., 1.2HCl inhibited the human MCH-induced cellular Ca2+ flux with IC50 of 6 μg/mL.


IT S10743-47-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazoline derivs. as melanin-concentrating hormone (MCH) receptor antagonists for prevention and/or treatment of obesity, obesity-related diseases, anxiety, or depression)

SAAED


10743642

L6 ANSWER 17 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 510743-47-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[[cis-4-[[4-(dimethylamino)-2-quinazolinyl]amino]cyclohexyl]methyl]-2-methyl-1,5-diphenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L6 ANSWER 18 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:790826 CAPLUS
 DOCUMENT NUMBER: 142:219202
 TITLE: Bioisosteric Replacements of the Pyrazole Moiety of Rimonabant: Synthesis, Biological Properties, and Molecular Modeling Investigations of Thiazoles, Triazoles, and Imidazoles as Potent and Selective CB1 Cannabinoid Receptor Antagonists
 AUTHOR(S): Lange, Jos H. M.; van Stuijvenberg, Herman H.; Coolen, Hein K. A. C.; Adolfs, Tiny J. P.; McCreary, Andrew C.; Keizer, Hiskias G.; Wals, Henri C.; Veerman, Willem; Boret, Alice J. M.; de Looff, Mouter; Verveer, Peter C.; Kruse, Chris G.
 CORPORATE SOURCE: Research Laboratories, Solvay Pharmaceuticals, Weesp, 1381 CP, Neth.
 SOURCE: Journal of Medicinal Chemistry (2005), 48(6), 1823-1838
 CODEN: JMCHMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 142:219202
 GI




AB Series of thiazoles, triazoles, and imidazoles were designed as bioisosteres, based on the 1,5-diarylpyrazole motif that is present in the potent CB1 receptor antagonist rimonabant. A number of target compds. were synthesized and evaluated in cannabinoid (hCB1 and hCB2) receptor assays. The thiazoles, triazoles, and imidazoles elicited in vitro CB1 antagonistic activities and in general exhibited considerable CB1 vs CB2 receptor subtype selectivities, thereby demonstrating to be cannabinoid bioisosteres of the original diarylpyrazole class. Some key representatives in the imidazole series showed potent pharmacol. in vivo activities after oral administration in both a CB agonist-induced hypotension model and a CB agonist-induced hypothermia model. Mol. modeling studies showed a close three-dimensional structural overlap

L6 ANSWER 18 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 relationship between the imidazole I and rimonabant. A structure-activity (SAR) study revealed a close correlation between the biol. results in the imidazole and pyrazole series.
 IT 505074-51-1P 796875-36-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (Preparation of imidazole, thiazole, and triazole analogs of rimonabant as potent and selective CB1 cannabinoid receptor antagonists)
 RN 505074-51-1 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 796875-36-0 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N,N-diethyl-5-methyl- (9CI) (CA INDEX NAME)



IT 505073-66-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Preparation of imidazole, thiazole, and triazole analogs of rimonabant as potent and selective CB1 cannabinoid receptor antagonists)
 RN 505073-66-5 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N,N-diethyl-5-methyl- (9CI) (CA INDEX NAME)
 SAEED

L6 ANSWER 18 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 diethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 55
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


10743642

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:589538 CAPLUS
 DOCUMENT NUMBER: 141:140442
 TITLE: Preparation of pyrrole and imidazole derivatives as
 CB
 INVENTOR(S): 1 receptor inverse agonists
 Werner; Mayweg, Alexander; Marty, Hans Peter; Mueller,
 Narquizian, Robert; Meidhart, Werner; Pflieger,
 Philippe; Roever, Stephan
 PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
 SOURCE: PCT Int. Appl., 197 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NO 2004060870	A1	20040722	WO 2003-EP14720	20031222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,				
TG CA 2511859	A1	20040722	CA 2003-2511859	20031222
AU 2003298227	A1	20040729	AU 2003-298227	20031222
US 2004167129	A1	20040826	US 2003-743642	20031222
EP 1583742	A1	20051012	EP 2003-795949	20031222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017926	A	20051129	BR 2003-17926	20031222
CN 1735593	A	20060215	CN 2003-80108268	20031222
JP 2006521281	T	20060921	JP 2004-564210	20031222
PRIORITY APPLN. INFO.:			EP 2003-3	A 20030102
			WO 2003-EP14720	W 20031222

OTHER SOURCE(S): MARPAT 141:140442
 GI

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB Title compds. I (X = C, N; R1 = H, alkyl; R2 = alkyl, cycloalkyl, etc.; R3 = cycloalkyl, Ph, substituted Ph, etc.; R4 = heteroaryl, Ph, substituted Ph, etc.; R5, R6 = H, alkyl, halomethyl; m = 0, 1, 2) and pharmaceutically acceptable salts are prepared. Thus, 1-cyclohexylmethyl-2-methyl-5-(4-pyrrolidin-1-yl)phenyl-1H-pyrrole-3-carboxylic acid butylamide was prepared and showed excellent affinity for CB 1 receptor. Formulations containing I were given. The compds. are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB 1 receptors.
 IT 725740-41-OP 725740-43-2P 725740-63-6P
 725740-74-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrrole and imidazole derivs. as CB 1 receptor inverse agonists)
 RN 725740-41-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-2-methyl-5-(4-(1-pyrrolidinyl)phenyl)- (9CI) (CA INDEX NAME)




RN 725740-43-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-5-(2,5-

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 dimethoxyphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 725740-63-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[3,5-bis(trifluoromethyl)phenyl]-N-butyl-1-(cyclohexylmethyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 725740-74-9 CAPLUS
 CN 1H-Imidazole-4-carboxamide, N-butyl-1-(cyclohexylmethyl)-2-(2-methoxyphenyl)-5-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 725743-35-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrrole and imidazole derivs. as CB 1 receptor inverse agonists)
 RN 725743-35-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[[1-(cyclohexylmethyl)-5-(2,5-dimethoxyphenyl)-2-methyl-1H-pyrrol-3-yl]carbonyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



PAGE 1-A

SAAED

10743642


L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 2-A




IT 725740-23-8P 725740-24-9P 725740-25-0P
 725740-26-1P 725740-27-2P 725740-28-3P
 725740-29-4P 725740-30-7P 725740-31-8P
 725740-32-9P 725740-33-0P 725740-34-1P
 725740-35-2P 725740-36-3P 725740-37-4P
 725740-38-5P 725740-39-6P 725740-42-1P
 725740-44-3P 725740-45-4P 725740-46-5P
 725740-47-6P 725740-49-8P 725740-50-1P
 725740-51-2P 725740-53-4P 725740-58-9P
 725740-59-0P 725740-60-3P 725740-62-5P
 725740-66-9P 725740-67-0P 725740-71-6P
 725740-72-7P 725740-73-8P 725740-75-0P
 725740-77-2P 725740-80-7P 725740-81-8P
 725740-87-4P 725740-89-6P 725740-90-9P
 725740-92-1P 725740-93-2P 725740-94-3P
 725740-95-4P 725740-96-5P 725740-97-6P
 725740-98-7P 725741-22-0P 725741-23-1P
 725741-32-2P 725741-33-3P 725741-34-4P
 725741-36-6P 725741-37-7P 725741-55-9P
 725741-56-0P 725741-57-1P 725741-67-3P
 725741-69-5P 725741-70-8P 725741-71-9P
 725741-72-0P 725741-73-1P 725741-75-3P
 725741-78-6P 725741-87-7P 725741-92-4P
 725741-93-5P 725741-98-0P 725741-99-1P
 725742-08-5P 725742-10-9P 725742-13-2P
 725742-17-6P 725742-19-8P 725742-34-7P
 725742-35-8P 725742-38-1P 725742-39-2P
 725742-43-8P 725742-44-9P 725742-47-2P
 725742-48-3P 725742-52-9P 725742-56-3P
 725742-62-1P 725742-89-2P 725742-92-7P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrrole and imidazole derivs. as CB 1 receptor inverse agonists)
 RN 725740-23-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-2-methyl-5-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 725740-24-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-5-(3,4-dichlorophenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 725740-25-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-5-(4-methoxyphenyl)-2-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 725740-26-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-5-(3-methoxyphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 725740-27-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-5-(4-cyanophenyl)-2-methyl- (9CI) (CA INDEX NAME)


L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 725740-28-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-2-methyl-5-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 725740-29-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-2-methyl-5-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-butyl-1-(cyclohexylmethyl)-2-methyl- (9CI) (CA INDEX NAME)




SAEED


10743642

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 725740-30-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-
N-butyl-5-(4-chlorophenyl)-1-(cyclohexylmethyl)-
2-methyl- (9CI) (CA INDEX NAME)




RN 725740-31-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-2-methyl-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 725740-32-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-5-(2,4-dichlorophenyl)-2-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 725740-35-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-5-(2,4-dimethoxyphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 725740-36-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-5-(4-bromophenyl)-2-methyl- (9CI) (CA INDEX NAME)




SAEED

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 725740-33-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-5-(2-methoxyphenyl)-
2-methyl- (9CI) (CA INDEX NAME)




RN 725740-34-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-5-(4-fluorophenyl)-
2-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 725740-37-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-5-(3-cyanophenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 725740-38-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-5-(2,4-dimethylphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 725740-39-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-5-(4-(difluoromethoxy)phenyl)-2-methyl- (9CI) (CA INDEX NAME)

10743642

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 725740-42-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-2-methyl-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 725740-44-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-5-(3,4-difluorophenyl)-2-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 725740-45-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-5-(3-chlorophenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 725740-46-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-5-(2-chlorophenyl)-2-methyl- (9CI) (CA INDEX NAME)


L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 725740-47-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-2-methyl-5-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 725740-49-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-5-(3,4-dimethoxyphenyl)-2-methyl- (9CI) (CA INDEX NAME)




L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 725740-50-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-5-(2-naphthalenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 725740-51-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-5-(2-chlorophenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 725740-53-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-5-(2-naphthalenyl)-2-methyl- (9CI) (CA INDEX NAME)


SAAED

10743642

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 725740-58-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-5-(2,5-difluorophenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 725740-59-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-5-(4-hydroxy-3-methoxyphenyl)-2-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 725740-60-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-5-(3-fluorophenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 725740-62-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-5-(2,5-dichlorophenyl)-2-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 725740-66-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-butyl-1-(cyclohexylmethyl)-5-(2,5-dimethoxyphenyl)-N,2-dimethyl- (9CI) (CA INDEX NAME)



RN 725740-67-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(cyclohexylmethyl)-5-(2,5-dimethoxyphenyl)-2-methyl-N-[(1R)-1-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




SAEED

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 725740-71-6 CAPLUS
CN 1H-Imidazole-4-carboxamide, N-butyl-1-(2-chlorophenyl)-1-(cyclohexylmethyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 725740-72-7 CAPLUS
CN 1H-Imidazole-4-carboxamide, N-butyl-1-[(4-chlorophenyl)methyl]-2-(4-methoxyphenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 725740-73-8 CAPLUS
CN 1H-Imidazole-4-carboxamide, N-butyl-1-(cyclohexylmethyl)-2-(4-methoxyphenyl)-5-methyl- (9CI) (CA INDEX NAME)

10743642


L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 725740-75-0 CAPLUS
 CN 1H-imidazole-4-carboxamide, N-butyl-1-[(4-chlorophenyl)methyl]-2-(2-methoxyphenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 725740-77-2 CAPLUS
 CN 1H-imidazole-4-carboxamide, N-butyl-1-(cyclopropylmethyl)-2-(2-methoxyphenyl)-5-methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 725740-89-6 CAPLUS
 CN 1H-pyrrole-3-carboxamide, 1-(cyclohexylmethyl)-5-(2,5-dimethoxyphenyl)-N-(3-hydroxypropyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 725740-90-9 CAPLUS
 CN 1H-pyrrole-3-carboxamide, 1-(cyclohexylmethyl)-N-(cyclopropylmethyl)-5-(2,5-dimethoxyphenyl)-2-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 725740-80-7 CAPLUS
 CN 1H-imidazole-4-carboxamide, N-butyl-1-(2-cyclohexylethyl)-2-(2-methoxyphenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 725740-81-8 CAPLUS
 CN 1H-imidazole-4-carboxamide, N-butyl-2-(2-chlorophenyl)-1-(cyclopropylmethyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 725740-87-4 CAPLUS
 CN 1H-imidazole-4-carboxamide, N-butyl-2-(2-chlorophenyl)-1-(2-cyclohexylethyl)-5-methyl- (9CI) (CA INDEX NAME)


L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 725740-92-1 CAPLUS
 CN 1H-pyrrole-3-carboxamide, 1-(cyclohexylmethyl)-5-(2,5-dimethoxyphenyl)-N-(2-furanylmethyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 725740-93-2 CAPLUS
 CN 1H-pyrrole-3-carboxamide, 1-(cyclohexylmethyl)-5-(2,5-dimethoxyphenyl)-2-methyl-N-[(3-methyl-2-thienyl)methyl]- (9CI) (CA INDEX NAME)




RN 725740-94-3 CAPLUS
 CN 1H-pyrrole-3-carboxamide, 1-(cyclohexylmethyl)-5-(2,5-dimethoxyphenyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)


SAAED

10743642

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 725740-95-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-(cyclohexylmethyl)-5-(2,5-dimethoxyphenyl)-2-methyl-N-[(3,3,3-trifluoropropyl)- (9CI) (CA INDEX NAME)




RN 725740-96-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-(cyclohexylmethyl)-5-(2,5-dimethoxyphenyl)-2-methyl-N-[(1S)-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 725741-23-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-(cyclohexylmethyl)-5-(2,5-dimethoxyphenyl)-N-[(2-methoxyethyl)-2-methyl]- (9CI) (CA INDEX NAME)




SAEED

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 725740-97-6 CAPLUS
 CN 1H-Imidazole-4-carboxamide, N-butyl-2-(5-chloro-2-methoxyphenyl)-1-(cyclohexylmethyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 725740-98-7 CAPLUS
 CN 1H-Imidazole-4-carboxamide, N-butyl-2-(5-chloro-2-methoxyphenyl)-1-(2-cyclohexylethyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 725741-22-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-(cyclohexylmethyl)-5-(2,5-dimethoxyphenyl)-2-methyl-N-(4-piperidinylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 725741-21-9
 CMF C27 H39 N3 O3

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 725741-32-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-(cyclohexylmethyl)-5-(2,5-dimethoxyphenyl)-N-(2-hydroxyethyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 725741-33-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-(cyclohexylmethyl)-N-[(5-cyclopropyl-1H-pyrazol-3-yl)methyl]-5-(2,5-dimethoxyphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 725741-34-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-(cyclohexylmethyl)-5-(2,5-dimethoxyphenyl)-2-methyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

10743642

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A




RN 725741-36-6 CAPLUS
CN 1H-imidazole-4-carboxamide, N-butyl-1-(cyclohexylmethyl)-5-methyl-2-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)


PAGE 2-A



L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 725741-37-7 CAPLUS
CN 1H-imidazole-4-carboxamide, N-butyl-1-(2-cyclohexylethyl)-5-methyl-2-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 725741-55-9 CAPLUS
CN 1H-imidazole-4-carboxamide, N-butyl-1-(cyclohexylmethyl)-5-methyl-2-(4-methylphenyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 725741-56-0 CAPLUS
CN 1H-imidazole-4-carboxamide, N-butyl-1-(2-cyclohexylethyl)-5-methyl-2-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 725741-57-1 CAPLUS
CN 1H-pyrrole-3-carboxamide, 5-(3,5-difluorophenyl)-2-methyl-1-(2-phenylethyl)-N-(3,3,3-trifluoropropyl)- (9CI) (CA INDEX NAME)




RN 725741-67-3 CAPLUS
CN 1H-imidazole-4-carboxamide, 1-(cyclohexylmethyl)-2-(5-fluoro-2-methylphenyl)- (9CI) (CA INDEX NAME)

SAEED

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 725741-69-5 CAPLUS
CN 1H-imidazole-4-carboxamide, N-butyl-2-(5-chloro-2-methylphenyl)-1-(cyclohexylmethyl)-5-methyl-N-(3,3,3-trifluoropropyl)- (9CI) (CA INDEX NAME)




RN 725741-70-8 CAPLUS
CN 1H-imidazole-4-carboxamide, 2-(4-chloro-2-methylphenyl)-1-(cyclohexylmethyl)-5-methyl-N-(3,3,3-trifluoropropyl)- (9CI) (CA INDEX NAME)

10743642

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 725741-71-9 CAPLUS
 CN 1H-imidazole-4-carboxamide, N-butyl-1-(2-cyclohexylethyl)-2-(5-fluoro-2-methylphenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 725741-72-0 CAPLUS
 CN 1H-imidazole-4-carboxamide, 2-(5-chloro-2-methylphenyl)-1-(2-cyclohexylethyl)-5-methyl-N-(3,3,3-trifluoropropyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 725741-78-6 CAPLUS
 CN 1H-imidazole-4-carboxamide, N-butyl-2-(4-chloro-2-methylphenyl)-1-(cyclohexylmethyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 725741-87-7 CAPLUS
 CN 1H-pyrrole-3-carboxamide, 5-[3,5-bis(trifluoromethyl)phenyl]-1-[(3-fluorophenyl)methyl]-2-methyl-N-[(1R)-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 725741-73-1 CAPLUS
 CN 1H-imidazole-4-carboxamide, 2-(5-chloro-2-methylphenyl)-1-(2-cyclohexylethyl)-5-methyl-N-(3,3,3-trifluoropropyl)- (9CI) (CA INDEX NAME)




RN 725741-75-3 CAPLUS
 CN 1H-imidazole-4-carboxamide, 2-(4-chloro-2-methylphenyl)-1-(2-cyclohexylethyl)-5-methyl-N-(3,3,3-trifluoropropyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 725741-92-4 CAPLUS
 CN 1H-pyrrole-3-carboxamide, 5-(2,5-dimethoxyphenyl)-2-methyl-1-(2-phenylethyl)-N-(3,3,3-trifluoropropyl)- (9CI) (CA INDEX NAME)




RN 725741-93-5 CAPLUS
 CN 1H-pyrrole-3-carboxamide, N-(cyclopropylmethyl)-5-(2,5-dimethoxyphenyl)-2-methyl-1-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 725741-98-0 CAPLUS
 CN 1H-pyrrole-3-carboxamide, 5-(2,5-dimethoxyphenyl)-1-[2-(3-fluorophenyl)ethyl]-2-methyl-N-(3,3,3-trifluoropropyl)- (9CI) (CA INDEX NAME)

SAEED

10743642


L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
NAME)

RN 725741-99-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
N-(cyclopropylmethyl)-5-(2,5-dimethoxyphenyl)-1-
(2-(3-fluorophenyl)ethyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 725742-08-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[3,5-bis(trifluoromethyl)phenyl]-1-
(cyclohexylmethyl)-2,4-dimethyl-N-[(1S)-1-methylpropyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 725742-17-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(cyclopropylmethyl)-5-(5-fluoro-2-
methoxyphenyl)-2-methyl-N-[(1R)-1-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725742-19-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(cyclohexylmethyl)-5-(5-fluoro-2-
methoxyphenyl)-2-methyl-N-(3,3,3-trifluoropropyl)- (9CI) (CA INDEX NAME)



RN 725742-34-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(cyclohexylmethyl)-5-(2,5-dichlorophenyl)-2-
methyl-N-[(2R)-tetrahydro-2-furanyl]methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

SAEED

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.

RN 725742-10-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[3,5-bis(trifluoromethyl)phenyl]-1-
(cyclopropylmethyl)-2-methyl-N-[(1S)-1-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 725742-13-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide,
5-(5-fluoro-2-methoxyphenyl)-2-methyl-N-[(1S)-1-
methylpropyl]-1-(2-phenylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 725742-35-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(cyclohexylmethyl)-5-(2,5-dichlorophenyl)-2-
methyl-N-[(1R,2S)-tetrahydro-2-furanyl]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 725742-38-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(cyclohexylmethyl)-5-(2,5-difluorophenyl)-N-
[(1R,2S)-2-hydroxycyclohexyl]methyl)-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10743642

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 725742-39-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(cyclohexylmethyl)-5-(2,5-difluorophenyl)-N-[(1R,2R)-2-hydroxycyclohexylmethyl]-2-methyl-, rel. (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 725742-43-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(cyclohexylmethyl)-5-(2,4-dichloro-5-fluorophenyl)-N-[(1-hydroxycyclohexyl)methyl]-2-methyl-, (9CI) (CA INDEX NAME)

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 725742-44-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(cyclohexylmethyl)-N-(cyclopropylmethyl)-5-(2,4-dichloro-5-fluorophenyl)-2-methyl-, (9CI) (CA INDEX NAME)




RN 725742-47-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N,1-bis(cyclohexylmethyl)-2-methyl-5-[2-(trifluoromethoxy)phenyl]-, (9CI) (CA INDEX NAME)

L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 725742-48-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(cycloheptylmethyl)-1-(cyclohexylmethyl)-2-methyl-5-[2-(trifluoromethoxy)phenyl]-, (9CI) (CA INDEX NAME)




RN 725742-52-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(cyclohexylmethyl)-5-[2-fluoro-5-(trifluoromethyl)phenyl]-2-methyl-N-[(tetrahydro-2-furanyl)methyl]-, (9CI) (CA INDEX NAME)


L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 725742-56-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[2-chloro-5-(trifluoromethyl)phenyl]-1-(cyclohexylmethyl)-N-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-2-methyl-, (9CI) (CA INDEX NAME)




RN 725742-62-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[2-chloro-4,5-difluorophenyl]-N,1-bis(cyclohexylmethyl)-2-methyl-, (9CI) (CA INDEX NAME)




SAEED

10743642


L6 ANSWER 19 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 725742-89-2 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 2-(5-chloro-2-fluorophenyl)-1-(2-cyclopropylethyl)-5-methyl-N-[2-(tetrahydro-2H-pyran-4-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 725742-92-7 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 2-[2-chloro-5-(trifluoromethyl)phenyl]-1-(cyclohexylethyl)-5-methyl-N-[2-(tetrahydro-2H-pyran-4-yl)ethyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 20 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 AB Imidazole and triazole deriva. were prepared for use as selective COX-1 inhibitors for treatment and/or prevention of inflammatory conditions, various pains, collagen diseases, autoimmune diseases, thrombosis, cancer or neurodegenerative diseases. Thus, 4-PhCH2OCH2CH2C6H4NHC(=NH)C6H4OMe-4 which was cyclized with BrCH2COCF3 and debenzylated to give the imidazole I. I had IC50 for COX-1 inhibition of < 0.01 and an analgesic coefficient relative to controls of > 1.5.
 IT 726194-19-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of imidazole and triazole deriva. useful as selective COX-1 inhibitors)
 RN 726194-19-0 CAPLUS
 CN 1H-Imidazole-4-carboxamide, N-ethyl-1-(4-hydroxyphenyl)-2-(4-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)




IT 726196-53-8P 726196-54-9P 726196-55-0P
 RN 726196-56-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of imidazole and triazole deriva. useful as selective COX-1 inhibitors)
 RN 726196-53-8 CAPLUS
 CN 1H-Imidazole-4-carboxamide, N-ethyl-2-(4-methoxyphenyl)-N-methyl-1-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 20 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:589415 CAPLUS
 DOCUMENT NUMBER: 141:140441
 TITLE: Preparation of imidazole and triazole derivatives useful as selective COX-1 inhibitors
 Inventor(S): Takahashi, Fumie; Nakagawa, Toshiya; Matsushima, Yuji;
 Patent Assignee(S): Nakamura, Katsuya
 Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 211 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004060367	A1	20040722	WO 2003-JP15921	20031212
W:	AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003288746	A1	20040729	AU 2003-288746	20031212
PRIORITY APPLN. INFO.:			AU 2002-953602	A 20021230
			AU 2003-901804	A 20030415
			AU 2003-903928	A 20030728
			WO 2003-JP15921	W 20031212


OTHER SOURCE(S): MARPAT 141:140441
 GI



L6 ANSWER 20 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 726196-54-9 CAPLUS
 CN 1H-Imidazole-4-carboxamide, N-ethyl-1-(4-hydroxyphenyl)-2-(4-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 726196-55-0 CAPLUS
 CN 1H-Imidazole-4-carboxamide, N,N-diethyl-2-(4-methoxyphenyl)-1-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 726196-56-1 CAPLUS
 CN 1H-Imidazole-4-carboxamide, N,N-diethyl-1-(4-hydroxyphenyl)-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

SAAED

10743642

L6 ANSWER 20 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




IT 726194-18-9P 726194-27-0P 726194-30-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
 USES (Uses)

(preparation of imidazole and triazole deriva. useful as selective
 COX-1 inhibitors)

RN 726194-18-9 CAPLUS


CN 1H-Imidazole-4-carboxamide, N-ethyl-1-[4-(2-hydroxyethoxy)phenyl]-2-(4-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 726194-27-0 CAPLUS


CN 1H-Imidazole-4-carboxamide, 1-[4-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethoxy]phenyl]-N-ethyl-2-(4-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 20 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 726194-30-5 CAPLUS

CN 1H-Imidazole-4-carboxamide, 1-[4-(2-aminoethoxy)phenyl]-N-ethyl-2-(4-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)



IT 726194-29-2P 726194-34-9P 726194-35-0P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazole and triazole deriva. useful as selective
 COX-1 inhibitors)

RN 726194-29-2 CAPLUS


CN 1H-Imidazole-4-carboxamide, 1-[4-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethoxy]phenyl]-N,N-diethyl-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 20 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 726194-34-9 CAPLUS

CN 1H-Imidazole-4-carboxamide, 1-[4-(2-aminoethoxy)phenyl]-N,N-diethyl-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 726194-35-0 CAPLUS

CN 1H-Imidazole-4-carboxamide, 1-[4-[2-[(aminocarbonyl)amino]ethoxy]phenyl]-N-ethyl-2-(4-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 726194-37-2 CAPLUS

CN 1H-Imidazole-4-carboxamide, 1-[4-[2-[(aminocarbonyl)amino]ethoxy]phenyl]-N,N-diethyl-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

SAEED

L6 ANSWER 20 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



10743642

L6 ANSWER 21 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 2004:515489 CAPLUS
 DOCUMENT NUMBER: 141:54345
 TITLE: Preparation of pyrazoles and imidazoles as cannabinoid

INVENTOR(S): CBI receptor antagonists.
 Dow, Robert Lee; Hammond, Marlys
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 102 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004052864	A1	20040624	WO 2003-1B5835	20031203
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,				
US 2004122074	A1	20040624	US 2003-702149	20031104
CA 2505887	A1	20040624	CA 2003-2505887	20031203
AU 2003286315	A1	20040630	AU 2003-286315	20031203
EP 1572662	A1	20050914	EP 2003-777058	20031203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017096	A	20051025	BR 2003-17096	20031203
JP 2006514942	T	20060518	JP 2004-558286	20031203
PRIORITY APPLN. INFO.:			US 2002-432911P	P 20021212
			WO 2003-1B5835	W 20031203

OTHER SOURCE(S): MARPAT 141:54345
 GI



L6 ANSWER 22 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:153570 CAPLUS
 DOCUMENT NUMBER: 140:391240
 TITLE: Potent imidazole and triazole CB1 receptor antagonists

AUTHOR(S): Dyck, Brian; Goodfellow, Val S.; Phillips, Teresa; Grey, Jonathan; Haddach, Mustapha; Rowbottom, Martin; Naeve, Gregory S.; Brown, Brock; Saunders, John
 CORPORATE SOURCE: Departments of Medicinal Chemistry, Pharmacology and Molecular Biology, Neurocrine Biosciences Inc., San Diego, CA, 92121, USA
 SOURCE: Biorganic & Medicinal Chemistry Letters (2004), 14(5), 1151-1154
 CODEN: BMCL58; ISSN: 0960-894X
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 140:391240
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Diarylimidazolecarboxamides and diaryltriazolecarboxamides related to SR141716 were synthesized and tested for binding to the human CB1 receptor. Suitably substituted imidazoles are comparably potent to the clin. candidate, whereas the analogous triazoles are less so due to the absence of an addnl. substituent on the azole ring. Example compds. thus prepared and evaluated were derivs. of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide (SR 141716) (I), such as 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(hexahydro-1H-azepin-1-yl)-1H-1,2,4-triazole-3-carboxamide (II) and

1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-(hexahydrocyclopenta(c)pyrrol-2(1H)-yl)-5-methyl-1H-imidazole-4-carboxamide (III).

IT 683208-91-5P 683208-95-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of imidazolecarboxamides and triazolecarboxamides related to SR 141716 and study of their activity as cannabinoid CB1 receptor antagonists)

RN 683208-91-5 CAPLUS
 CN 1H-Imidazole-4-carboxamide,
 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 21 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


AB Title compds. (I); X = C and Y = H, or X = N and Y = C; R1 = H, alkyl, halo, cyano; R2, R3 = (CH2)nAr; m, n = 0-2; p = 0-3; Ar = (substituted) aryl, heteroaryl; L = CO, CR4OR5; R4 = H, alkyl; R5 = H, alkyl; R5R8, R5R9 = CH2CH2, CH2CO; R6, R7 = H, alkyl; R6R7 = atoms to form a (partially) saturated carbocyclic ring; R8, R9 = H, alkyl, CO(CH2)mR10, SO2(CH2)nR10, (CH2)pR10; R8R9 = atoms to form a 4-8 membered (partially) saturated ring; R10 = (substituted) alkyl, (partially) saturated cycloalkyl, aryl, heteroaryl, heterocyclyl; dotted lines = bonds for form an aromatic ring], were prepared for treatment of obesity, alcoholism, or tobacco abuse (no data). Thus,

2-(benzylisopropylamino)-1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]ethanone hydrochloride was stirred with NaBH4 in EtOH to give 2-(benzylisopropylamino)-1-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazol-3-yl]ethanol.


IT 709036-65-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrazoles and imidazoles as cannabinoid CB1 receptor antagonists)

RN 709036-65-7 CAPLUS


CN 1H-Imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-methoxy-N-methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 22 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 683208-95-9 CAPLUS
 CN 1H-Imidazole-4-carboxamide,
 1-(4-chlorophenyl)-N-[2-(4-chlorophenyl)ethyl]-
 2-(2,4-dichlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

10743642

L6 ANSWER 23 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:144003 CAPLUS

DOCUMENT NUMBER: 139:144003

TITLE: Substituted imidazoles as cannabinoid receptor modulators, their preparation, and their therapeutic use

INVENTOR(S): Hegmann, William K.; Qi, Hongbo; Shah, Shrenik K.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 128 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003063781	A2	20030807	WO 2003-US2351	20030124
WO 2003063781	A3	20031211		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004248956	A1	20041209	US 2004-501060	20040709
PRIORITY APPLN. INFO.:			US 2002-352743P	P 20020129
			WO 2003-US2351	W 20030124

OTHER SOURCE(S): MARPAT 139:144003

AB Comps. of the invention are antagonists and/or inverse agonists of the cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The comps. of the invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuroinflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The comps. are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well

as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

IT 572889-96-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(imidazole derivative cannabinoid receptor modulators, preparation,

and

L6 ANSWER 24 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:1376829 CAPLUS

DOCUMENT NUMBER: 138:385424

TITLE: Imidazole-4-carboxamide derivatives, and their preparation and use for treatment of obesity

INVENTOR(S): Smith, Roger A.; O'Connor, Stephen J.; Wirtz, Stephan-Nicholas; Wong, Wai C.; Choi, Soongyu; Kluender, Harold C. E.; Su, Ning; Wang, Gan; Achebe, Furehi; Wang, Shihong

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA

SOURCE: PCT Int. Appl., 225 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040107	A1	20030515	WO 2002-US30545	20020924
WO 2003040107	A8	20040729		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2459745	A1	20030515	CA 2002-2459745	20020924
US 2004063691	A1	20040401	US 2002-255049	20020924
US 6960601	B2	20051101		
EP 1432691	A1	20040630	EP 2002-780365	20020924
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012986	A	20040817	BR 2002-12986	20020924
HU 200402376	A2	20050228	HU 2004-2376	20020924
CN 1599724	A	20050323	CN 2002-818693	20020924
JP 20050508384	T	20050331	JP 2003-542153	20020924
NZ 531841	A	20050930	NZ 2002-531841	20020924
CN 1865248	A	20061122	CN 2006-10091513	20020924
NO 2004001216	A	20040505	NO 2004-1216	20040323
ZA 2004003035	A	20050421	ZA 2004-3035	20040421
US 2005256167	A1	20051117	US 2005-133751	20050520
PRIORITY APPLN. INFO.:			US 2001-324473P	P 20010924
			CN 2002-818693	A3 20020924
			US 2002-255049	A3 20020924
			WO 2002-US30545	W 20020924

OTHER SOURCE(S): MARPAT 138:385424


GI

L6 ANSWER 23 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

therapeutic use)

RN 572889-96-4 CAPLUS

CN 1H-Imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 24 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

ACCESSION NUMBER: 2003:1376829 CAPLUS

DOCUMENT NUMBER: 138:385424

TITLE: Imidazole-4-carboxamide derivatives, and their preparation and use for treatment of obesity

INVENTOR(S): Smith, Roger A.; O'Connor, Stephen J.; Wirtz, Stephan-Nicholas; Wong, Wai C.; Choi, Soongyu; Kluender, Harold C. E.; Su, Ning; Wang, Gan; Achebe, Furehi; Wang, Shihong

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA

SOURCE: PCT Int. Appl., 225 pp.


CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



AB The invention relates to imidazole derivs. I, which have been found to suppress appetite and induce weight loss [wherein: R1, R2 = alkyl, (un)substituted Ph, alkyl, naphthyl, benzyl, (un)saturated or aromatic heterocyclyl; R3 = H, alkyl, benzyl, Cl, or Br; X = (a) CONR4R5 or (b) CONHSO2R10; (a) R4 = H or alkyl; R5 = (un)substituted alkyl, bicycloalkyl,

benzyl, phenethyl, piperidinyl or pyrrolidinyl, NR6R7, etc.; or NR4R5 = (un)substituted (un)saturated heterocyclyl; R6 = H or alkyl; R7 = alkyl

or (un)substituted Ph; or NR6R7 = (un)substituted (un)saturated

heterocyclyl; or

(b) R10 = (un)substituted alkyl, benzocyclohexyl, or benzocyclopentyl; including pharmaceutical salts and esters]. The invention also provides methods for synthesis of the comps., pharmaceutical comps. comprising them, and methods of using such comps. for inducing weight loss and

treating

obesity and obesity-related disorders. Such disorders include dyslipidemia, hypertriglyceridemia, hypertension, diabetes, syndrome X, atherosclerotic disease, cardiovascular disease, cerebrovascular disease, peripheral vessel disease, cholesterol gallstones, cancer, menstrual abnormalities, infertility, polycystic ovaries, osteoarthritis, and sleep apnea. I are also claimed for use in regulating appetite, treating

bulimia, treating CNS disorders, treating cognition and memory disorders, and treating substance or behavioral addiction. I may also be administered or formed into pharmaceutical comps. in combination with other agents for similar treatments, e.g., antiobesity agents, hypolipidemics, and antihypertensives. Approx. 50 synthetic examples of both invention comps. and intermediates are given, and several tables of comps. I (480 total comps.) are provided. For instance,

2-chloro-N-(4-chlorophenyl)benzencarboximidamide was cyclized with Et 3-bromo-2-oxopentanoate in the presence of K2CO3 to give an imidazole-4-carboxylate ester, which reacted with 1-aminopiperidine in

the presence of AlMe3 to give title compound II. In the fasted-refed acute


SAAED

10743642

L6 ANSWER 24 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
feeding assay in rats, invention compd. III at 10 mg/kg orally reduced
food consumption by 31-53% vs. control.

IT 527369-03-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of imidazolecarboxamide derivs. as
antiobesity
agents)


RN 527369-03-5 CAPLUS
CN 1H-Imidazole-4-carboxamide, 2-(2-chlorophenyl)-1-(4-chlorophenyl)-N-
methoxy-N-methyl- (9CI) (CA INDEX NAME)



IT 527367-84-6P 527368-19-0P 527368-57-6P
527368-66-7P 527368-71-4P 527370-18-9P
527370-23-6P 527370-28-1P 527370-33-8P
527370-47-4P 527370-52-1P 527370-68-9P
527370-73-6P 527370-77-0P 527370-82-7P
527370-87-2P 527371-19-1P 527371-24-0P
527371-53-5P 527375-14-0P 527375-87-7P
527375-90-2P 527375-94-6P 527375-99-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(drug candidate; preparation of imidazolecarboxamide derivs. as
antiobesity
agents)

RN 527367-84-6 CAPLUS
CN 1H-Imidazole-4-carboxamide, 2-(2-chlorophenyl)-1-(4-chlorophenyl)-N-
cyclohexyl-N-methyl- (9CI) (CA INDEX NAME)


L6 ANSWER 24 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl

RN 527368-66-7 CAPLUS
CN 1H-Imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-
methyl-N-[(1R,2R)-2-(methylamino)cyclohexyl]-, monohydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




● HCl


RN 527368-71-4 CAPLUS
CN 1H-Imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-
methyl-N-[(1S,2S)-2-(methylamino)cyclohexyl]-, monohydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 24 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 527368-19-0 CAPLUS
CN 1H-Imidazole-4-carboxamide,
2-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N,N-
dimethyl- (9CI) (CA INDEX NAME)




RN 527368-57-6 CAPLUS
CN 1H-Imidazole-4-carboxamide,
2-(2-chlorophenyl)-1-(4-chlorophenyl)-N-methyl-
N-(1-methyl-3-pyrrolidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 24 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● HCl

RN 527370-18-9 CAPLUS
CN 1H-Imidazole-4-carboxamide,
2-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-[2-
(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 527370-23-6 CAPLUS
CN 1H-Imidazole-4-carboxamide,
2-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-[2-
(diethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 527370-28-1 CAPLUS


SAEED

10743642

L6 ANSWER 24 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1H-Imidazole-4-carboxamide,
 2-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(2-(dimethylamino)ethyl)- (9CI) (CA INDEX NAME)




RN 527370-33-8 CAPLUS
 CN 1H-Imidazole-4-carboxamide,
 2-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 527370-47-4 CAPLUS
 CN 1H-Imidazole-4-carboxamide,
 2-(2-chlorophenyl)-1-(4-chlorophenyl)-N-propyl- (9CI) (CA INDEX NAME)

L6 ANSWER 24 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1H-Imidazole-4-carboxamide,
 2-(2-chlorophenyl)-1-(4-chlorophenyl)-N-[(2,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 527370-77-0 CAPLUS
 CN 1H-Imidazole-4-carboxamide,
 2-(2-chlorophenyl)-1-(4-chlorophenyl)-N-[3-(1-pyrrolidinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 527370-82-7 CAPLUS
 CN 1H-Imidazole-4-carboxamide,
 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)


L6 ANSWER 24 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 527370-52-1 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 2-(2-chlorophenyl)-1-(4-chlorophenyl)-N-(1-ethylpropyl)- (9CI) (CA INDEX NAME)




RN 527370-68-9 CAPLUS
 CN 1H-Imidazole-4-carboxamide,
 2-(2-chlorophenyl)-1-(4-chlorophenyl)-N-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 527370-73-6 CAPLUS

L6 ANSWER 24 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 527370-87-2 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 1-(4-chlorophenyl)-N-[3-(1-pyrrolidinyl)propyl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 527371-19-3 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 2-(2,4-dichlorophenyl)-N-[[[1R,2R]-2-hydroxycycloheptyl)methyl]-1-(4-methoxyphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




SAAED

10743642


L6 ANSWER 24 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 527371-24-0 CAPLUS
CN 1H-Imidazole-4-carboxamide, 2-(2,4-dichlorophenyl)-N-[(1R,2S)-2-hydroxycyclohexylmethyl]-1-(4-methoxyphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 527371-53-5 CAPLUS
CN 1H-Imidazole-4-carboxamide, 2-(2-chlorophenyl)-1-(4-chlorophenyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 527375-14-0 CAPLUS
CN 1H-Imidazole-4-carboxamide, 2-(2-chlorophenyl)-1-(4-chlorophenyl)-N-[(2,4-dimethoxyphenyl)methyl]-N-[(2R,3R)-1,2,3,4-tetrahydro-3-hydroxy-2-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L6 ANSWER 24 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 527375-87-7 CAPLUS
CN 1H-Imidazole-4-carboxamide, 2-(2,4-dichlorophenyl)-N-[(1R)-2-hydroxy-1-phenylethyl]-1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 527375-90-2 CAPLUS
CN 1H-Imidazole-4-carboxamide, 2-(2,4-dichlorophenyl)-N-[(1S)-2-hydroxy-1-phenylethyl]-1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L6 ANSWER 24 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 527375-94-6 CAPLUS
CN 1H-Imidazole-4-carboxamide, 2-(2-chlorophenyl)-1-(4-chlorophenyl)-N-[(1R)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 527375-99-1 CAPLUS
CN 1H-Imidazole-4-carboxamide, 2-(2-chlorophenyl)-1-(4-chlorophenyl)-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

SAEED

L6 ANSWER 24 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

10743642

L6 ANSWER 25 OF 43 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 2003:282325 CAPLUS
 DOCUMENT NUMBER: 138:321285
 TITLE: Preparation of quinazoline-2,4-diamines as MCH receptor antagonists
 INVENTOR(S): Sekiguchi, Yoshinori; Kanuma, Koake; Omomura, Katsunori; Tran, Thuy-anh; Kramex, Bryan Aubrey; Beeley, Nigel Robert Arnold
 PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 1171 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003028641	A2	20030410	WO 2002-US31059	20020930
WO 2003028641	A3	20030828		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2460594	A1	20030410	CA 2002-2460594	20020930
EP 1432693	A2	20040630	EP 2002-800388	20020930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CN 1582281	A	20050216	CN 2002-823940	20020930
JP 200553237	T	20050804	JP 2003-531977	20020930
PRIORITY APPL. INFO.:			US 2001-326463P	P 20011001
			US 2001-326758P	P 20011002
			WO 2002-US31059	W 20020930

OTHER SOURCE(S): MARPAT 138:321285
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. QLYR1[Q = I, C:(NH)NH2; R1 = (un)substituted alkyl, alkenyl, cycloalkyl, etc.; L = II-IV (wherein R4 = H, alkyl; R5 = H, alkyl, alkyl substituted by a substituted carbocyclic aryl), etc.; Y = SO2, CO, (CH2)m; m = 0-1] which act as MCH receptor antagonists, and are useful for prophylaxis or treatment of obesity, obesity related disorders.


L6 ANSWER 26 OF 43 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 2003:261815 CAPLUS
 DOCUMENT NUMBER: 138:287674
 TITLE: Preparation of 1H-imidazole-4-carboxamides as CB1 agonists, partial agonists, or antagonists for treatment of psychiatric and neurological disorders
 INVENTOR(S): Kruse, Cornelis G.; Lange, Josephus H. M.; Herremans, Arnoldus H. J.; Van Stuijvenberg, Herman H.
 PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V., Neth.
 SOURCE: PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003027076	A2	20030403	WO 2002-EP10434	20020917
WO 2003027076	A3	20031120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
TW 231757	B	20050501	TW 2002-91119798	20020830
CA 2457444	A1	20030403	CA 2002-2457444	20020917
EP 1438296	A2	20040721	EP 2002-772314	20020917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012481	A	20040824	BR 2002-12481	20020917
CN 1556703	A	20041222	CN 2002-818346	20020917
JP 200504805	T	20050217	JP 2003-530667	20020917
HU 200402150	A2	20050228	HU 2004-2150	20020917
IN 2004CN00574	A	20060113	IN 2004-CN574	20040317
ZA 2004002188	A	20050429	ZA 2004-2188	20040318
NO 2004001171	A	20040621	NO 2004-1171	20040319
US 2004235854	A1	20041125	US 2004-490019	20040319
US 2005054679	A1	20050210	US 2004-912171	20040806
US 7109216	B2	20060919		
PRIORITY APPL. INFO.:			EP 2001-203851	A 20010921
			WO 2002-EP10434	W 20020917
			US 2004-490019	A2 20040319
			US 2004-574939P	P 20040528


OTHER SOURCE(S): MARPAT 138:287674
 GI

L6 ANSWER 25 OF 43 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
 anxiety, or depression, were prep. Thus, hydrogenation of benzyl cis-4-(4-(4-dimethylamino)quinazolin-2-ylamino)cyclohexylmethylcarbamate followed by reacting the resulting intermediate with 4-bromo-2-trifluoromethoxybenzaldehyde in the presence of NaBH(OAc)3 and AcOH in CH2Cl2, and treatment of the product with 4N HCl in EtOAc afforded 34% cis-V.2HCl which showed IC50 of 6 nM against MCH receptor.
 IT 510743-47-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of quinazoline-2,4-diamines as MCH receptor antagonists)
 RN 510743-47-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[(cis-4-[(4-(dimethylamino)-2-quinazolinyl)amino]cyclohexyl)methyl]-2-methyl-1,5-diphenyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L6 ANSWER 26 OF 43 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




AB Title compds. I [wherein R = (un)substituted Ph, thienyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, or triazinyl; R1 = (un)substituted Ph or pyridinyl; R2 = H or (cyclo)alkyl or (cyclo)alkenyl optionally interrupted by S, O, or N; R3 = (un)substituted (cyclo)alkyl, (cyclo)alkoxy, bicycloalkyl, tricycloalkyl, or (cyclo)alkenyl optionally interrupted by N, O, or S; or R3 = pyridinyl or Ph when R4 = H; or R3 = NR5R6 when R2 = H or Me; or NR3R3 = (un)substituted heterocyclyl; R4 = H, halo, CN, carbamoyl, formyl, acetyl, CF3CO, FCH2CO, ECCO, sulfamoyl, MeSO2, MeS, or (un)substituted alkyl; R5 and R6 = independently alkyl, or NR5R6 = (un)substituted heterocyclyl; and prodrugs, stereoisomers, and salts thereof] were prepared as potent cannabinoid (CB1) receptor agonists, partial agonists, or antagonists (no data). For example, reaction of 4-chloroaniline with 2,4-dichlorobenzonitrile in the presence of sodium bis(trimethylsilyl)amide in THF provided N-(4-chlorophenyl)-2,4-dichlorobenzene-carboxamide (42%). Cyclization of the carboxamide with Et 3-bromo-2-oxopropanoate in a solution of NaHCO3 and isopropanol gave the imidazolecarboxylate (29%), which was converted to the imidazolecarboxyl chloride (no data). Amidation with 1-aminopiperidine using TEA in CH2Cl2 afforded II (26%). I are useful for the treatment of psychiatric and neurol. disorders, as well as and other diseases involving cannabinoid neurotransmission (no data).
 IT 505073-32-5P, N-(Benzyl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-methyl-1H-imidazole-4-carboxamide 505073-48-3P, 1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-5-ethyl-N-pentyl-1H-imidazole-4-carboxamide 505073-56-3P, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-(4-fluorobenzyl)-1H-imidazole-4-carboxamide 505073-63-2P, 1-(4-chlorophenyl)-2-(2-methoxy-4-chlorophenyl)-N-pentyl-1H-imidazole-4-carboxamide 505073-66-5P, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N,N-diethyl-1H-imidazole-4-carboxamide 505073-71-2P, 1-(4-chlorophenyl)-N-(2,2,2-trifluoroethyl)-2-(2-trifluoromethyl-4-chlorophenyl)-1H-imidazole-4-carboxamide 505073-89-2P, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N,N,5-trimethyl-1H-imidazole-4-carboxamide 505074-05-5P, 1-(4-chlorophenyl)-2-(2-methoxy-4-chlorophenyl)-5-methyl-N-pentyl-1H-imidazole-4-carboxamide 505074-13-5P, 1-(4-chlorophenyl)-2-(2-fluoro-4-chlorophenyl)-5-methyl-N-pentyl-1H-imidazole-4-carboxamide 505074-18-0P, 2-(2-chlorophenyl)-1-(3-fluorophenyl)-5-methyl-N-pentyl-1H-imidazole-4-carboxamide

SAEED


10743642

L6 ANSWER 26 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 505074-21-5P, 2-(2-Chlorophenyl)-1-(3-fluorophenyl)-N-[2-(4-fluorophenyl)ethyl]-5-methyl-1H-imidazole-4-carboxamide
 505074-32-8P, 1-(4-Chlorophenyl)-2-(2,4-dichlorophenyl)-N-(2-fluoroethyl)-5-methyl-1H-imidazole-4-carboxamide 505074-36-2P, 1-(4-Chlorophenyl)-2-(2,4-dichlorophenyl)-N-(4-fluorobenzyl)-5-methyl-1H-imidazole-4-carboxamide 505074-50-0P, 1-(4-Chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-N-[3-(trifluoromethyl)benzyl]-1H-imidazole-4-carboxamide 505074-51-1P, 1-(4-Chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-N-[4-(trifluoromethyl)benzyl]-1H-imidazole-4-carboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (CBI modulator; prepn. of imidazolecarboxamides as CBI agonists, partial agonists, or antagonists for treatment of psychiatric and neurol. disorders)
 RN 505073-32-5 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 505073-48-3 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-5-ethyl-N-pentyl- (9CI) (CA INDEX NAME)


L6 ANSWER 26 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 505073-66-5 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 505073-71-2 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-[4-chloro-2-(trifluoromethyl)phenyl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




SAEED

L6 ANSWER 26 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 505073-56-3 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 505073-63-2 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 2-(4-chloro-2-methoxyphenyl)-1-(4-chlorophenyl)-N-pentyl- (9CI) (CA INDEX NAME)

L6 ANSWER 26 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 505073-89-2 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N,N,5-trimethyl- (9CI) (CA INDEX NAME)




RN 505074-05-5 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 2-(4-chloro-2-methoxyphenyl)-1-(4-chlorophenyl)-5-methyl-N-pentyl- (9CI) (CA INDEX NAME)




RN 505074-13-5 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 2-(4-chloro-2-fluorophenyl)-1-(4-chlorophenyl)-5-methyl-N-pentyl- (9CI) (CA INDEX NAME)

10743642


L6 ANSWER 26 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 505074-18-0 CAPLUS
CN 1H-imidazole-4-carboxamide,
2-(2-chlorophenyl)-1-(3-fluorophenyl)-5-methyl-
N-pentyl- (9CI) (CA INDEX NAME)




RN 505074-21-5 CAPLUS
CN 1H-imidazole-4-carboxamide,
2-(2-chlorophenyl)-1-(3-fluorophenyl)-N-(2-(4-
fluorophenyl)ethyl)-5-methyl- (9CI) (CA INDEX NAME)





RN 505074-32-8 CAPLUS
CN 1H-imidazole-4-carboxamide,
1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-(2-


L6 ANSWER 26 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 505074-51-1 CAPLUS
CN 1H-imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-
methyl-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 26 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
fluoroethyl)-5-methyl- (9CI) (CA INDEX NAME)

RN 505074-36-2 CAPLUS
CN 1H-imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-
[(4-fluorophenyl)methyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 505074-50-0 CAPLUS
CN 1H-imidazole-4-carboxamide, 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-
methyl-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 27 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:261810 CAPLUS
DOCUMENT NUMBER: 138:287520
TITLE: Preparation and use of pyrrolicarboxamides and
pyrrolicarbohydrazides for treating obesity
INVENTOR(S): Smith, Roger A.; Kluender, Harold C. E.; Su, Ning;
Lavoie, Rico C.; Fan, Jianmei
PATENT ASSIGNEE(S): Bayer Pharmaceutical Corporation, USA
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003027069	A1	20030403	WO 2002-US30543	20020924
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RM: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NI, SD, TD, TG				
CA 2461144	A1	20030403	CA 2002-2461144	20020924
EP 1432679	A1	20040630	EP 2002-799637	20020924
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005532982	T	20051104	JP 2003-530660	20020924
US 2004267028	A1	20041230	US 2004-489031	20040305
PRIORITY APPLN. INFO.:				US 2001-324441P
				P 20010924
				WO 2002-US30543
				W 20020924

OTHER SOURCE(S): MARPAT 138:287520
GI



AB This invention relates to pyrrolicarboxamides and pyrrolicarbohydrazides (shown as I; variables defined below; e.g. 1-(2-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-N-(1-piperidinyl)-1H-pyrrole-3-carboxamide hydrochloride) that suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compds., pharmaceutical compns.

SAEED

10743642


L6 ANSWER 27 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
comprising the compds., and methods of using such compns. for inducing wt. loss and treating obesity and obesity-related disorders. Although the methods of prepn. are not claimed, 6 example prepn. of 1 and/or intermediates and characterization data for .apprx.50 examples of 1 are included. Seven pharmaceutical formulations are listed. Comps. of this invention are active in a fasted-refed acute feeding assay. For example, when 1-(2-chlorophenyl)-5-(4-chlorophenyl)-2-methyl-N-(1-piperidinyl)-1H-pyrrole-3-carboxamide hydrochloride was dosed at 10 mg/kg p.o., food consumption was reduced (relative to the food consumption obsd. for the vehicle control group) by up to 25% when measured at time points = 30-240 min. Likewise, when 1-(2-chlorophenyl)-5-(4-methoxyphenyl)-2,4-dimethyl-N-[(4-(trifluoromethyl)phenyl)-1H-pyrrole-3-carbohydrazide hydrochloride was dosed at 10 mg/kg p.o., food consumption was reduced by up to 35%. For 1: R1 and R2 = Ph optionally substituted with 21 halogen, (C1-C6)alkyl, (C1-C6)alkoxy, trifluoromethyl, hydroxy, cyano, or nitro;

R3 = H; R4 = CH3; R5 = H or (C1-C6)alkyl; R6 = substituted cyclohexyl; (un)substituted (C1-C5)alkyl; cyclopentyl, cycloheptyl or cyclo(C3-C7)alkyl; (C1-C3)alkyl, each of which may be optionally substituted; substituted benzyl; substituted phenyl; piperidin-4-yl, piperidin-3-yl, or pyrrolidin-3-yl, each of which may be optionally substituted on the N atom of the piperidine or pyrrolidine ring; -NR7R8. Or R5 and R6, taken together with the N atom to which they are attached, form a 5- to 10-membered satd. heterocyclic radical contg. at least one addnl. N atom, with optional substitution. Or R5 and R6, taken together with the N atom to which they are attached, form a 1-piperidinyl, 1-pyrrolidinyl, or 1-morpholino group, which is substituted; addnl. details are given in the claims.


IT 504405-39-4P, N-(Cyclohexylmethyl)-2-methyl-1,5-diphenyl-1H-pyrrole-3-carboxamide 504405-67-8P, N-[(4-Chlorophenyl)methyl]-1-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-2-methyl-1H-pyrrole-3-carboxamide 504405-68-9P, N-[(4-Fluorophenyl)methyl]-1-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-2-methyl-1H-pyrrole-3-carboxamide 504405-69-0P, N-[(4-(Trifluoromethyl)phenyl)methyl]-1-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-2-methyl-1H-pyrrole-3-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation and use of pyrrolicarboxamides for treating obesity-related disorders)
RN 504405-39-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(cyclohexylmethyl)-2-methyl-1,5-diphenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 27 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 504405-67-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-chlorophenyl)-N-[(4-chlorophenyl)methyl]-1-(2,4-dichlorophenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 504405-68-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-chlorophenyl)-N-[(4-fluorophenyl)methyl]-1-(2,4-dichlorophenyl)-2-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 27 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 504405-69-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-chlorophenyl)-N-[(4-(trifluoromethyl)phenyl)methyl]-1-(2,4-dichlorophenyl)-2-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

SAEED

L6 ANSWER 27 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

10743642

L6 ANSWER 28 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:713119 CAPLUS

DOCUMENT NUMBER: 137:362535

TITLE: Computer-Aided Design of Selective COX-2 Inhibitors: Comparative Molecular Field Analysis, Comparative Molecular Similarity Indices Analysis, and Docking Studies of Some 1,2-Diarylimidazole Derivatives
 AUTHOR(S): Desiraju, G. R.; Gopalakrishnan, B.; Jetti, R. K. R.; Nagaraju, A.; Raveendra, D.; Sarma, J. A. R. P.; Sobhia, M. E.; Thilagavathi, R.
 CORPORATE SOURCE: School of Chemistry, University of Hyderabad, Hyderabad, 500 046, India
 SOURCE: Journal of Medicinal Chemistry (2002), 45(22), 4847-4857
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Comparative mol. field anal. and comparative mol. similarity indexes anal.
 were performed on 114 analogs of 1,2-diarylimidazole to optimize their cyclooxygenase-2 (COX-2) selective antiinflammatory activities. These studies produced models with high correlation coeffs. and good predictive abilities. Docking studies were also carried out wherein these analogs were docked into the active sites of both COX-1 and COX-2 to analyze the receptor ligand interactions that confer selectivity for COX-2. The most active mol. in the series adopts an orientation similar to that of SC-558 (4-[5-(4-bromophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-benzensulfonamide) inside the COX-2 active site while the least active mol. optimizes in a different orientation. In the active site, there are some strong hydrogen-bonding interactions observed between residues

His90, Arg513, and Phe518 and the ligands. Addnl., a correlation of the quant. structure-activity relation data and the docking results is found to validate each other and suggests the importance of the binding step in overall drug action.
 IT 189628-32-8
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (QSAR ComPA, COMSIA anal. and docking studies of arylimidazole deriva. as COX-2 inhibitors)
 RN 189628-32-8 CAPLUS
 CN 1H-imidazole-4-carboxamide, 2-(4-chlorophenyl)-N,N-diethyl-1-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 29 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 2001:868414 CAPLUS

DOCUMENT NUMBER: 136:20006

TITLE: Preparation of pyrrole derivatives as tyrosine phosphatase inhibitors for preventive and therapeutic drugs for diseases such as diabetes
 INVENTOR(S): Hiroshi
 Takeda Chemical Industries, Ltd., Japan
 PATENT ASSIGNEE(S): PCT Int. Appl., 337 pp.
 SOURCE: CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001090067	A1	20011129	WO 2001-JP4201	20010521
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CP, CG, CI, CH, GA, GN, GW, ML, MR, NE, NG, TD, TG				
CA 2410338	A1	20011129	CA 2001-2410338	20010521
AU 2001058784	A5	20011203	AU 2001-58784	20010521
JP 2002121186	A	20020423	JP 2001-150910	20010521
EP 1284260	A1	20030219	EP 2001-932153	20010521
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003144338	A1	20030731	US 2002-276674	20021115
US 6911468	B2	20050628		
PRIORITY APPL. INFO.:			JP 2000-154441	A 20000522
			JP 2000-247954	A 20000810
			WO 2001-JP4201	W 20010521


OTHER SOURCE(S): MARPAT 136:20006
 GI



AB Comps. of the general formula (I) or salts thereof [wherein X1 and X2

SAEED

L6 ANSWER 28 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 29 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

each a free valency or a spacer having a C1-20 main chain; one of R1 and R2 is a cyclic group which bears a substituent selected from among (1) carboxylated C1-6 alkoxy groups which may be substituted and (2) carboxylated C1-6 aliph. hydrocarbon groups which may be substituted and may further have other substituent, and the other is an optionally substituted cyclic group or hydrogen; and R3, R4 and R5 are each hydrogen or a substituent, or alternatively R4 together with R3 or R5 may form an optionally substituted ring, with the proviso that some comds. of the general formula I are excluded.) are prep. These comds. are useful as preventive and therapeutic drugs for diabetes, impaired glucose tolerance (IGT), tumors, autoimmune diseases, immunodeficiency, allergies, bone diseases, infections, joint diseases, hyperlipidemia, diabetes complications, obesity, cachexia, fatty liver, hypertension, liver diseases, polycystic ovary syndromes, muscular dystrophy, myocardial infarction, angina pectoris, cerebral infarction, syndrome X, high-blood insulin, inflammation, and arteriosclerosis or as improvers for insulin resistance or enhancers for insulin sensitivity or blood platelet aggregation inhibitors. Thus, cyclocondensation of 4-octylphenylamine with 1-(4-benzyloxyphenyl)-1,4-pentanedione in the presence of p-MeC6H4SO3H.H2O in PhMe under reflux for 12 h and hydrogenation of the resulting 1-(4-pentylphenyl)-2-methyl-5-(4-benzyloxyphenyl)-1H-pyrrole over 10% Pd-C in ethanol under hydrogen atm. gave

4-[1-(4-pentylphenyl)-5-methyl-1H-pyrrol-2-yl]phenol which underwent Mitsunobu reaction with (S)-2-hydroxy-3-phenylpropanoic acid Et ester using 1,1'-azobiscarbonyldipiperidine and Ph3P in PhMe at 80° for 12 h to give (2R)-2-[[4-[1-(4-pentylphenyl)-5-methyl-1H-pyrrol-2-yl]phenyl]oxy]-3-phenylpropanoic acid Et ester. The latter ester was converted into (2R)-2-[[4-[1-(4-pentylphenyl)-5-methyl-1H-pyrrol-2-yl]phenyl]oxy]-3-phenylpropanoic acid sodium salt (II). II showed IC50 of 0.09 µM against human protein tyrosine phosphatase-1B. Tablet formulations contg. specific I, e.g. (2R)-2-[[4-[1-(2-(4-bromophenyl)ethan-1-yl]-5-methyl-1H-pyrrol-2-yl]phenoxy]-3-phenylpropanoic acid, were described.


IT 176635-65-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (Preparation of pyrrole derivs. as tyrosine phosphatase inhibitors for preventive and therapeutic drugs for diseases such as diabetes)

RN 176635-65-3 CAPLUS
 CN Benzenepropanoic acid, α-[4-[1-(2-(4-bromophenyl)ethyl)-4-[(decylamino)carbonyl]-5-methyl-1H-pyrrol-2-yl]phenoxy]-, ethyl ester, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10743642

L6 ANSWER 29 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




IT 376635-66-4P, (2R)-2-[4-{1-[2-(4-bromophenyl)ethyl]-4-(decylaminocarbonyl)-5-methyl-1H-pyrrol-2-yl}phenoxy]-3-phenylpropanoic acid
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrrole derivs. as tyrosine phosphatase inhibitors for preventive and therapeutic drugs for diseases such as diabetes)
 RN 376635-66-4 CAPLUS
 CN Benzenepropanoic acid, α-[4-{1-[2-(4-bromophenyl)ethyl]-4-(decylaminocarbonyl)-5-methyl-1H-pyrrol-2-yl}phenoxy]-, (αR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 29 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L6 ANSWER 29 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

IT 376640-89-0P, N-Decyl-1-[4-(4-bromophenyl)-5-(4-methoxyphenyl)-2-methyl-1H-pyrrole-3-carboxamide 376640-91-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrrole derivs. as tyrosine phosphatase inhibitors for preventive and therapeutic drugs for diseases such as diabetes)
 RN 376640-89-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[2-(4-bromophenyl)ethyl]-N-decyl-5-(4-methoxyphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 376640-91-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[2-(4-bromophenyl)ethyl]-N-decyl-5-(4-hydroxyphenyl)-2-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 30 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:699248 CAPLUS
 DOCUMENT NUMBER: 136:2171
 TITLE: QSAR and k-Nearest Neighbor Classification Analysis of Selective Cyclooxygenase-2 Inhibitors Using Topologically-Based Numerical Descriptors
 AUTHOR(S): Kauffman, Gregory W.; Jurs, Peter C.
 CORPORATE SOURCE: Department of Chemistry, The Pennsylvania State University, University Park, PA, 16802, USA
 SOURCE: Journal of Chemical Information and Computer Sciences (2001), 41(6), 1553-1560
 CODEN: JCISD8; ISSN: 0095-2338
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Exptl. IC50 data for 314 selective cyclooxygenase-2 (COX-2) inhibitors are used to develop quantitation and classification models as a potential screening mechanism for larger libraries of target compds. Exptl. log(IC50) values ranged from 0.23 to ≥ 5.00. Numerical descriptors encoding solely topol. information are calculated for all structures and are used as inputs for linear regression, computational neural network, and classification anal. routines. Evolutionary optimization algorithms are then used to search the descriptor space for information-rich subsets which minimize the rms error of a diverse training set of compds. An eight-descriptor model was identified as a robust predictor of exptl. log(IC50) values, producing a root-mean-square error of 0.625 log units for an external prediction set of inhibitors which took no part in model development. A k-nearest neighbor classification study of the data set discriminating between active and inactive members produced a nine-descriptor model able to accurately classify 93.3% of the prediction set compds. correctly.
 IT 189628-32-8
 RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cyclooxygenase-2 inhibitor; QSAR and k-nearest neighbor classification anal. of selective cyclooxygenase-2 inhibitors using topol.-based numerical descriptors)
 RN 189628-32-8 CAPLUS
 CN 1H-Imidazole-4-carboxamide, 2-(4-chlorophenyl)-N,N-diethyl-1-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

10743642

L6 ANSWER 30 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 31 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN

1997:513627 CAPLUS
 ACCESSION NUMBER: 127:190737
 DOCUMENT NUMBER: 127:190737
 TITLE: Heterocyclo-substituted imidazoles for the treatment of inflammation
 INVENTOR(S): Khanna, Ish K.; Weier, Richard M.; Collins, Paul W.; Yu, Ui; Xu, Xiangdong; Partis, Richard A.; Koszyk, Francis J.; Huff, Renee M.
 PATENT ASSIGNEE(S): O.D. Searle and Co., USA; Khanna, Ish K.; Weier, Richard M.; Collins, Paul W.; Yu, Ui; Xu, Xiangdong; Partis, Richard A.; Koszyk, Francis J.; Huff, Renee M.
 M. SOURCE: PCT Int. Appl., 253 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9727181	A1	19970731	WO 1997-US300	19970124
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TO				
CA 2244837	A1	19970731	CA 1997-2244837	19970124
AU 9715739	A	19970820	AU 1997-15739	19970124
AU 730642	B2	20010308		
EP 880504	A1	19981202	EP 1997-901952	19970124
EP 880504	B1	20030402		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
FI				
JP 2000503987	T	20000404	JP 1997-526876	19970124
EP 1193265	A2	20020403	EP 2001-123289	19970124
EP 1193265	A3	20020410		
EP 1193265	B1	20061129		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
FI				
AT 236130	T	20030415	AT 1997-901952	19970124
PT 880504	T	20030329	PT 1997-901952	19970124
ES 2197983	T3	20040116	ES 1997-901952	19970124
AT 346849	T	20061215	AT 2001-123289	19970124
ZA 9700670	A	19980416	ZA 1997-670	19970127
AU 767993	B2	20031127	AU 2001-11100	20010109
US 2003036557	A1	20030220	US 2001-4944	20011205
US 6613789	B2	20030902		
US 2005096368	A1	20050505	US 2003-653399	20030902
US 2005256120	A1	20051117	US 2005-183016	20050715
PRIORITY APPLN. INFO.:			US 1996-592167	A1 19960126
			US 1994-282395	B2 19940728



L6 ANSWER 31 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

US 1995-464154 A2 19950605
 WO 1995-US9506 W 19950727
 AU 1997-15739 A3 19970124
 EP 1997-901952 A3 19970124
 WO 1997-US300 W 19970124
 US 1999-101493 B1 19990602
 US 2001-4944 A1 20011205
 US 2003-653399 A1 20030902

OTHER SOURCE(S): MARPAT 127:190737
 GI

L6 ANSWER 31 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 177662-75-8 CAPLUS
 CN 1H-imidazole-4-carboxamide, 2-(4-chlorophenyl)-N-methoxy-N-methyl-1-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



AB A class of imidazole deriva., for use in treating inflammation, is described. Comps. of particular interest are defined by formula I [R1, R2 = (un)substituted aryl, cycloalkenyl, cycloalkenyl, or heterocyclo; R3 = H, (un)substituted alkyl, acyl, cyano, alkoxy, alkylthio, alkylsulfonyl, cycloalkoxy, arylsulfonyl, halo, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, carboxyl, aminocarbonyl, aryloxy, aryl, heterocyclo, etc.;

R4 = H, alkyl, halo; R5 = OH, alkoxy; R6 = H; or R5R6 = pi bond; provided that at least one of R1 and R2 is aryl substituted with alkylsulfonyl, haloalkylsulfonyl, or aminosulfonyl, as well as their pharmaceutically acceptable salts. For instance, addition reaction of 2-cyano-4-methylpyridine with 4-(methylsulfonyl)aniline gave the corresponding amidine, which underwent cyclization with BrCH2COCP3, followed by acid-catalyzed dehydration of the formed 4-hydroxy-4,5-dihydroimidazole derivative, to give title compound II. In assays for inhibition of human cyclooxygenase (COX) in vitro, II had ID50 values of 0.5 and >100 μM for COX-2 and COX-1, resp.


IT 177662-75-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of heterocyclo-substituted imidazoles as antiinflammatories)

SAEED

10743642

L6 ANSWER 32 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1997:309987 CAPLUS
 DOCUMENT NUMBER: 126:324935
 TITLE: 1,2-Diarylimidazoles as potent, cyclooxygenase-2 selective and orally active antiinflammatory agents
 AUTHOR(S): Khanna, Ish K.; Weier, Richard M.; Yu, Yi; Xu, Xiang D.; Koszyk, Francis J.; Collins, Paul W.; Koboldt, Carol M.; Veenhuizen, Amy W.; Perkins, William E.; Casler, Jacquelyn J.; Masferrer, Jaime L.; Zhang, Yan.
 YAN: Y.; Gregory, Susan A.; Seibert, Karen; Isakson, Peter C.
 CORPORATE SOURCE: Discovery Medicinal Chemistry and Inflammatory Disease
 IL: Research, Searle Research and Development, Skokie, IL, 60077, USA
 SOURCE: Journal of Medicinal Chemistry (1997), 40(11), 1634-1647
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Series of 1,2-diarylimidazoles has been synthesized and found to contain highly potent and selective inhibitors of the human COX-2 enzyme. The paper describes a short synthesis of the target 1,2-diarylimidazoles starting with aryl nitriles. Different portions of the diarylimidazole were modified to establish SAR. Systematic variations of the substituents in the aryl ring has yielded very potent (IC₅₀ = 10-100 nm) and selective (1000-12500) inhibitors of the COX-2 enzyme. The study on the influence of substituents in the imidazole ring established that a CF₃ group at position 4 gives the optimum oral activity. A number of the diarylimidazoles showed excellent inhibition in the adjuvant induced arthritis model (e.g. ED₅₀ = 0.02 mpk for 22 and 34). The diarylimidazoles are also potent inhibitors of carrageenan-induced edema (ED₅₀ = 9-30 mpk) and hyperalgesia (ED₅₀ = 11-40 mpk). Several orally active diarylimidazoles show no GI toxicity in the rat and mouse up to 200 mpk.
 IT 189628-32-8P
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (synthesis and structure of 1,2-diarylimidazoles as cyclooxygenase selective and orally active antiinflammatory agents)
 RN 189628-32-8 CAPLUS
 CN 1H-imidazole-4-carboxamide, 2-(4-chlorophenyl)-N,N-diethyl-1-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 32 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




L6 ANSWER 33 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1997:231464 CAPLUS
 DOCUMENT NUMBER: 126:317382
 TITLE: Preparation of 1,2-diarylimidazoles as cyclooxygenase-2 inhibitors
 INVENTOR(S): Khanna, Ish K.; Weier, Richard M.; Collins, Paul W.; Yu, Yi; Xu, Xiangdong; Partis, Richard A.; Koszyk, Francis J.
 PATENT ASSIGNEE(S): G.D. Searle and Co., USA
 SOURCE: U.S., 65 pp., Cont.-in-part of U.S. Ser. No. 282,395, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5616601	A	19970401	US 1995-464154	19950605
CA 2195845	A1	19960208	CA 1995-2195845	19950727
WO 9603388	A1	19960208	WO 1995-US9506	19950727
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RN: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9532025	A	19960222	AU 1995-32025	19950727
EP 772600	A1	19970514	EP 1995-928164	19950727
EP 772600	B1	20020918		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 10503211	T	19980324	JP 1995-505972	19950727
AT 224374	T	20021015	AT 1995-928164	19950727
PT 772600	T	20030131	PT 1995-928164	19950727
ES 2183883	T3	20030401	ES 1995-928164	19950727
AU 767993	B2	20031127	AU 2001-11100	20010109
US 2003036557	A1	20030220	US 2001-4944	20011205
US 6613789	B2	20030902		
US 2005096368	A1	20050505	US 2003-653399	20030902
US 2005256120	A1	20051117	US 2005-183016	20050715
PRIORITY APPLN. INFO.:			US 1994-282395	B2 19940728
			US 1995-464154	A 19950605
			WO 1995-US9506	W 19950727
			AU 1997-15739	A3 19970124
			WO 1997-US300	W 19970124
			US 1999-101493	B1 19990602
			US 2001-4944	A1 20011205
			US 2003-653399	A1 20030902


OTHER SOURCE(S):
 GI: MARPAT 126:317382

SAEED

L6 ANSWER 33 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB Title compds. [I; 1 of R1, R2 = amino- or alkylsulfonyl-substituted (hetero)aryl and the other = (un)substituted (hetero)aryl; R3 = H, acyl, alkyl, (hetero)aryl, etc.; R4 = H, halo, alkyl; R5 = OH or alkoxy; R6 = H;
 H; R5R6 = bond] were prepared. Thus, 4-ClC6H4CN was aminated by 4-(MeO2S)C6H4NH2 and the product cyclocondensed with CF3COCH2Br to give, after dehydration, I [R1 = C6H4(SO2Me)-4, R2 = C6H4Cl-4, R3 = CF3, R4 = H, R5R6 = bond]. Data for biol. activity of I were given.
 IT 189295-82-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 1,2-diarylimidazoles as cyclooxygenase-2 inhibitors)
 RN 189295-82-7 CAPLUS
 CN 1H-imidazole-4-carboxamide, 1-[4-(aminosulfonyl)phenyl]-2-(4-chlorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




10743642


L6 ANSWER 34 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1996:363276 CAPLUS
 DOCUMENT NUMBER: 125:33646
 TITLE: 1,2-Substituted imidazolyl compounds for the treatment of inflammation
 INVENTOR(S): Khanna, Ish K.; Weier, Richard M.; Collins, Paul W.; Yu, Yi; Xu, Xiangdong; Huff, Renee M.; Partis, Richard
 PATENT ASSIGNEE(S): A.; Koeszyk, Francis J.
 SOURCE: G.D. Searle and Co., USA
 PCT Int. Appl., 249 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9603388	A1	19960208	WO 1995-US9506	19950727
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CP, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5616601	A	19970401	US 1995-464154	19950605
AU 9532025	A	19960222	AU 1995-32025	19950727
EP 772600	A1	19970514	EP 1995-928164	19950727
EP 772600	B1	20020918		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 10503211	T	19980324	JP 1995-505972	19950727
AT 224374	T	20021015	AT 1995-928164	19950727
AU 767993	B2	20031127	AU 2001-11100	20010109
US 2003036557	A1	20030220	US 2001-4944	20011205
US 6613789	B2	20030902		
US 2005096368	A1	20050505	US 2003-653399	20030902
US 2005256120	A1	20051117	US 2005-183016	20050715
PRIORITY APPLN. INFO.:			US 1994-282395	A 19940728
			US 1995-464154	A 19950605
			WO 1995-US9506	W 19950727
			AU 1997-15739	A3 19970124
			WO 1997-US300	W 19970124
			US 1999-101493	B1 19990602
			US 2001-4944	A1 20011205
			US 2003-653399	A1 20030902

L6 ANSWER 34 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L6 ANSWER 34 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 OTHER SOURCE(S): MARPAT 125:33646
 GI



AB A class of imidazolyl compds., which are selective inhibitors of cyclooxygenase 2 (COX 2), is described. The compds. are useful in treating inflammation and related disorders (arthritis, fever, and pain). Compds. of particular interest are I (R3 = H, (un)substituted alkyl, aralkyl, heterocycloalkyl, acyl, cyano, alkoxy, alkylthio, cycloalkoxy, halo, substituted carbonyl, sulfonyl, oxy, thio, aryl, and heteroaryl; R7 = alkyl or amino; R8 = ≥ 1 of H, halo, alkyl, haloalkyl, alkoxy, amino, haloalkoxy, cyano, CO2H, OH, hydroxyalkyl, alkoxyalkyl, alkylamino, nitro, and alkylthio), as well as certain heterocyclic analogs. For instance, condensation of 4-(methylsulfonyl)aniline-HCl with 3-cyanopyridine in the presence of Me3Al (34%), followed by cyclization of the resultant amidine with BrCH2COCP3 (60%), and dehydration of the obtained hydroxydihydroimidazole derivative using p-MeC6H4SO3H (23%), gave title compound II. In the carrageenan-induced rat paw edema and analgesia tests, II gave 57% inhibition of edema at 30 mg/kg orally, and 51% inhibition of hyperalgesic foot withdrawal at 10 mg/kg orally.

Inhibition data for recombinant COX 1 and 2 are also given.


IT 177662-75-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of imidazole deriva. as antiinflammatories)

RN 177662-75-8 CAPLUS
 CN 1H-imidazole-4-carboxamide, 2-(4-chlorophenyl)-N-methoxy-N-methyl-1-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 35 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1996:122149 CAPLUS
 DOCUMENT NUMBER: 124:289156
 TITLE: Synthesis of some new 4,5-diphenyl-3-(N-methyl/N,N-diethyl)carbamoyl-2-methyl-1-substituted-1H-pyrroles and their fungicidal activity
 AUTHOR(S): Sadenandam, Y. S.; Leelavathi, P.; Shetty, Meera M.
 CORPORATE SOURCE: Organic Chemistry Division-I, Indian Institute Chemical Technology, Hyderabad, 500 007, India
 SOURCE: Indian Journal of Heterocyclic Chemistry (1995), 5(2), 125-8
 CODEN: IJCHEI; ISSN: 0971-1627
 PUBLISHER: Lucknow University, Dep. of Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A number of new title compds. (6) have been synthesized by the reaction of N-methyl/N,N-diethylacetacetamide with benzoin and various alkyl, aryl and aralkylamines in the presence of formic acid. Compds. 6 showed appreciable antifungal activity mild bactericidal activity.

IT 175475-93-1P 175475-94-2P 175475-95-3P 175476-00-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and antimicrobial activity of)


RN 175475-93-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N,2-dimethyl-1-(4-methylphenyl)-4,5-diphenyl- (9CI) (CA INDEX NAME)




RN 175475-94-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N,2-dimethyl-1-(4-methylphenyl)-4,5-diphenyl- (9CI) (CA INDEX NAME)

10743642


L6 ANSWER 35 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 175475-95-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N,2-dimethyl-4,5-diphenyl- (9CI) (CA INDEX NAME)




RN 175476-00-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N,2-dimethyl-4,5-diphenyl-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




IT 175475-96-4P 175475-97-5P 175475-98-6P


L6 ANSWER 35 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 175475-99-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(3,4-dichlorophenyl)-N,2-dimethyl-4,5-diphenyl- (9CI) (CA INDEX NAME)




RN 175476-01-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N,2-dimethyl-4,5-diphenyl-1-(1-phenylethyl)- (9CI) (CA INDEX NAME)




L6 ANSWER 35 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

175475-99-7P 175476-01-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 175475-96-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-methoxyphenyl)-N,2-dimethyl-4,5-diphenyl- (9CI) (CA INDEX NAME)




RN 175475-97-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N,2-dimethyl-1-(2-nitrophenyl)-4,5-diphenyl- (9CI) (CA INDEX NAME)



RN 175475-98-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N,2-dimethyl-1-(4-nitrophenyl)-4,5-diphenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 36 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:124338 CAPLUS
DOCUMENT NUMBER: 118:124338
TITLE: Studies on anti-Candida agents with a pyrrole moiety. Synthesis and microbiological activity of some 3-(aminomethyl)-1,5-diaryl-2-methylpyrrole derivatives
AUTHOR(S): Cerreto, F.; Villa, A.; Retico, A.; Scalzo, M.
CORPORATE SOURCE: Dip. Studi Chim. Technol. Sostanze Biol. Attive, Univ.
SOURCE: La Sapienza, Rome, 00185, Italy
27(7), European Journal of Medicinal Chemistry (1992),
701-8
CODEN: EJMCA5; ISSN: 0223-5234
DOCUMENT TYPE: Journal
LANGUAGE: English
GI




AB The synthesis and anti-Candida activity of some 3-aminomethyl-1,5-diaryl-2-methylpyrroles, e.g., I (R = H, 4-Cl, 4-F, 2,4-Cl2; R1 = H, Cl; R2 = NMe2, NHPh, pyrrolidino, 1-imidazolyl, 4-methylpiperazin-1-yl) are reported. Some derivs. show a rather strong anti-Candida activity. On the basis of exptl. results, microbiol. activity of 1,5-diarylpyrroles appears to be mainly related to aminic nitrogen lone pair availability of C3 substituent of the pyrrole nucleus. The CS and N1 substituents play an important role in modulating biol. activity. Some structure-activity relationships are proposed.
IT 146204-81-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antifungal activity of)
RN 146204-81-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1,5-bis(4-chlorophenyl)-N,N,2-trimethyl- (9CI) (CA INDEX NAME)

SAAED

10743642

L6 ANSWER 36 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L6 ANSWER 37 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1993:120801 CAPLUS
 DOCUMENT NUMBER: 118:120801
 TITLE: Studies on anti-Candida agents with a pyrrole moiety. Synthesis and microbiological activity of some [(1-alkyl), (1-aryl) and (1-benzyl)-5-aryl-3-carboxamido-2-methyl]pyrrole derivatives
 AUTHOR(S): Scalzo, Marcello; Biava, Mariangela; Cerreto, Felice; Villa, Adelaide
 CORPORATE SOURCE: Dip. Studi Chim. Tecno., Univ. "La Sapienza", Rome, Italy
 SOURCE: Farmaco (1992), 47(7-8), 1047-53
 CODEN: FRMCE8; ISSN: 0014-827X
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The synthesis of some [(1-alkyl), (1-aryl) and (1-benzyl)-5-aryl-3-carboxamido-2-methyl]pyrrole derivs. is reported. Their activity against Candida strains was assessed and the structure-activity relationships for these compds. are discussed and related to structure-activity guidelines proposed for a series of previously studied 1,5-diarylpyrroles.

IT 146429-87-0P 146429-88-1P 146429-89-2P


146429-90-5P 146429-91-6P

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation and fungicidal activity of)

RN 146429-87-0 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N,N-bis(2-hydroxyethyl)-2-methyl-5-(4-nitrophenyl)-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 146429-88-1 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 1-[(4-chlorophenyl)methyl]-N,N-bis(2-hydroxyethyl)-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 37 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 146429-89-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 1-(2-chlorophenyl)-N,N-bis(2-hydroxyethyl)-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 146429-90-5 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N,N-bis(2-hydroxyethyl)-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 37 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 146429-91-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-N,N-bis(2-hydroxyethyl)-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




SAEED

10743642

L6 ANSWER 38 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1992:165918 CAPLUS
 DOCUMENT NUMBER: 117:165918
 TITLE: Pyrrole dicarboxylic acid derivatives and herbicides containing them
 INVENTOR(S): Ishikawa, Hiromichi; Morita, Takeshi; Nakamura, Toshiki; Yoshizawa, Hirokazu
 PATENT ASSIGNER(S): Hokko Chemical Industry Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
 CODEN: JKKXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04145078	A	19920519	JP 1990-265232	19901004
PRIORITY APPLN. INFO.: JP 1990-265232 19901004				

OTHER SOURCE(S): MARPAT 117:165918
 GI




AB Pyrrole dicarboxylic acid deriva. I [R1 = H, lower alkyl, Ph lower alkyl; R2 = OH, lower alkoxy, lower alkylthio, NR4R5 (R4, R5 = H, lower alkyl, 2,6-diethylphenyl); R3 = pyridyl, thienyl, furyl, CP3] and herbicides containing I as active ingredients are claimed. Thus, 7.1 g di-Me acetylenedicarboxylate, 12.8 g N-nicotinoylphenylglycine, and acetic anhydride were stirred at 140° for 1 h to give 10.0 g I (R1 = H, R2 = OMe, R3 = pyridyl; II). II 15, white carbon 15, Ca ligninsulfonate 3, polyoxyethylene nonylphenyl ether 2, Kieselguhr 5, and clay 60 parts were mixed to give a wettable powder. II at 50 g/10 are totally controlled Panicum Crus-galli, Aizawa canaliculatum, etc., without damaging rice,

vs. less effect for butachlor.


IT 143428-25-5P 143428-29-9P
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as herbicide)

RN 143428-25-5 CAPLUS
 CN 1H-Pyrrole-3,4-dicarboxamide, N,N'-diethyl-2-phenyl-1-(phenylmethyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 38 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 143428-29-9 CAPLUS
 CN 1H-Pyrrole-3,4-dicarboxamide, 2-phenyl-1-(2-phenylethyl)-N,N'-dipropyl-5-(2-thienyl)- (9CI) (CA INDEX NAME)




L6 ANSWER 39 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1992:128771 CAPLUS
 DOCUMENT NUMBER: 116:128771
 TITLE: Synthesis of 1H-imidazoles by the simple ring transformation of 5-acylaminothiuracils and 5-acylaminoimidin-4(3H)-ones
 AUTHOR(S): Matsuura, Izumi; Ueda, Taisei; Murakami, Nobutoshi; Nagai, Shinichi; Sakakibara, Jinseku
 CORPORATE SOURCE: Fac. Pharm. Sci., Nagoya City Univ., Nagoya, 467, Japan
 SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1991), (11), 2821-6
 CODEN: JCPRB4; ISSN: 0300-922X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 116:128771
 GI



AB 1,2-Disubstituted 4-alkylcarbamoyl-5-methyl-1H-imidazoles, e.g. I, and 2-substituted 5-methyl-4-phenylcarbamoyl-1H-imidazoles were synthesized from 5-acylamino-6-methyluracils, e.g. II, and 5-acylamino-6-methyl-3-phenylpyrimidin-4(3H)-ones by treatment with sodium hydroxide in ethanol. In the case of 5-acylaminoimidin-4(3H)-ones which possess an olefinic group in the acylamino group, 2-ethoxyethyl (or 2-ethoxypropyl)-5-methyl-4-phenylcarbamoyl-1H-imidazoles were prepared as major products and the corresponding 2-alkenyl-1H-imidazoles were only minor products. Compds. which contain an aryl function in their acylamino group gave glycine anilides as byproducts.

IT 120319-08-6P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)

RN 120319-08-6 CAPLUS
 CN 1H-Imidazole-4-carboxamide, N,5-dimethyl-1,2-diphenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 39 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

SAEED

10743642

L6 ANSWER 40 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1989:493768 CAPLUS
 DOCUMENT NUMBER: 111:93768
 TITLE: Synthesis and microbiological activity of new 1,5-diarylpyrroles
 AUTHOR(S): Scalzo, Marcello; Biava, Mariangela; Cerreto, Felice; Porretta, Giulio Cesare; Panico, Salvatore; Simonetti, Nicola
 CORPORATE SOURCE: Fac. Farm., Univ. La Sapienza, Rome, Italy
 SOURCE: European Journal of Medicinal Chemistry (1988), 23(6),

587-91
 CODEN: EJMCAS; ISSN: 0223-5234
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 111:93768
 AB A series of 1,5-diarylpyrrole deriva. were synthesized and tested in vitro

for their activity against bacteria and fungi. Forty-eight deriva. were evaluated for their antifungal activity against *Candida albicans* and various strains of *Candida* species. The antibacterial activity of 10 deriva. was evaluated against gram-pos. and gram-neg. bacteria. Structure-activity relations are discussed.

IT 122121-42-0P 122121-43-1P 122121-44-2P
 122121-45-3P 122121-47-5P 122121-48-6P
 122121-49-7P 122121-50-0P 122121-52-2P
 122121-53-3P 122121-54-4P 122121-55-5P
 122121-57-7P 122121-58-8P 122121-59-9P
 122121-60-2P 122121-62-4P 122121-63-5P
 122121-64-6P 122121-65-7P 122121-67-9P
 122121-68-0P 122121-69-1P 122121-70-4P
 122121-71-5P 122121-72-6P 122121-73-7P
 122148-64-5P


RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation and antimicrobial activity of)

RN 122121-42-0 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 1-(4-fluorophenyl)-N-hexyl-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 40 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 122121-43-1 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-dodecyl-1-(4-fluorophenyl)-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 122121-44-2 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 1-(4-fluorophenyl)-2-methyl-5-(4-nitrophenyl)-N-phenylmethyl- (9CI) (CA INDEX NAME)

L6 ANSWER 40 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 122121-45-3 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[(4-chlorophenyl)methyl]-1-(4-fluorophenyl)-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 122121-47-5 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 1-(4-bromophenyl)-N-hexyl-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 40 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 122121-48-6 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 1-(4-bromophenyl)-N-dodecyl-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 122121-49-7 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 1-(4-bromophenyl)-2-methyl-5-(4-nitrophenyl)-N-phenylmethyl- (9CI) (CA INDEX NAME)




SAEED

10743642

L6 ANSWER 40 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 122121-50-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-(4-bromophenyl)-N-[(4-chlorophenyl)methyl]-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 122121-52-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-hexyl-2-methyl-5-(4-nitrophenyl)-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 122121-53-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-dodecyl-2-methyl-5-(4-nitrophenyl)-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 40 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 122121-57-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[2-chloro-5-(trifluoromethyl)phenyl]-N-hexyl-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 122121-58-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[2-chloro-5-(trifluoromethyl)phenyl]-N-dodecyl-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 40 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 122121-54-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 2-methyl-5-(4-nitrophenyl)-N-(phenylmethyl)-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 122121-55-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[(4-chlorophenyl)methyl]-2-methyl-5-(4-nitrophenyl)-1-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 40 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 122121-59-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-[2-chloro-5-(trifluoromethyl)phenyl]-2-methyl-5-(4-nitrophenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 122121-60-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[(4-chlorophenyl)methyl]-1-[2-chloro-5-(trifluoromethyl)phenyl]-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

10743642

L6 ANSWER 40 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 122121-62-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(3,5-dichlorophenyl)-N-hexyl-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 122121-63-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(3,5-dichlorophenyl)-N-dodecyl-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 40 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 122121-67-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(3,4-dichlorophenyl)-N-hexyl-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 122121-68-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(3,4-dichlorophenyl)-N-dodecyl-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 40 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 122121-64-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(3,5-dichlorophenyl)-2-methyl-5-(4-nitrophenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 122121-65-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[(4-chlorophenyl)methyl]-1-(3,5-dichlorophenyl)-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 40 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 122121-69-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(3,4-dichlorophenyl)-2-methyl-5-(4-nitrophenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 122121-70-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[(4-chlorophenyl)methyl]-1-(3,4-dichlorophenyl)-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

10743642

L6 ANSWER 40 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 122121-71-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-N-dodecyl-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 122121-72-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-2-methyl-5-(4-nitrophenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 40 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L6 ANSWER 40 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)







RN 122121-73-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[(4-chlorophenyl)methyl]-1-(2,4-dichlorophenyl)-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 122148-64-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-N-hexyl-2-methyl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 41 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 1989:192713 CAPLUS
 DOCUMENT NUMBER: 110:192713
 TITLE: A novel ring transformation of 5-acylamino-6-methyluracils and 5-acylamino-6-methyl-4-(3H)-pyrimidin-4(3H)-ones into imidazoles
 AUTHOR(S): Ueda, Taisei; Matsura, Izumi; Murakami, Nobutoshi; Nagai, Shinichi; Sakakibara, Jinsaku; Goto, Masafumi
 CORPORATE SOURCE: Fac. Pharm. Sci., Nagoya City Univ., Nagoya, 467, Japan
 SOURCE: Tetrahedron Letters (1988), 29(36), 4607-10
 CODEN: TELEAY; ISSN: 0040-4039
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 110:192713
 GI



AB 1,3-Disubstituted 5-acylamino-6-methyluracils I (R1-R3 = Ph, Me) were transformed into 1,2-disubstituted 4-alkylcarbamoyl-5-methyl-1H-imidazoles II (same R's) by treatment with 5% aqueous NaOH in EtOH. Similarly, reaction of 5-acylamino-6-methyl-3-phenyl-4-(3H)-pyrimidinones III (R4 = Me, Ph, Et, Pr) with 5% aqueous sodium hydroxide in ethanol gave 2-substituted 5-methyl-4-phenylcarbamoyl-1H-imidazoles IV (same R4's).

IT RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (preparation and crystal structure of)

RN 120319-08-6 CAPLUS
 CN 1H-Imidazole-4-carboxamide, N,5-dimethyl-1,2-diphenyl- (9CI) (CA INDEX NAME)




SAEED

10743642

L6 ANSWER 41 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L6 ANSWER 42 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1989:36649 CAPLUS
 DOCUMENT NUMBER: 110:36649
 TITLE: Compounds with antibacterial and antifungal activity. Part IV. Synthesis and microbiological activity of new 1,5-diarylpyrrole derivatives
 AUTHOR(S): Scalzo, M.; Porretta, G. C.; Chimentì, F.; Casanova, M. C.; Panico, S.; Simonetti, N.
 CORPORATE SOURCE: Dip. Chim. Tecnol. Sostanze Biol. Attive, Univ. "La Sapienza", Rome, Italy
 SOURCE: Farmaco, Edizione Scientifica (1988), 43(9), 665-76
 DOCUMENT TYPE: CODEN: FRPSAX; ISSN: 0430-0920
 LANGUAGE: Journal
 OTHER SOURCE(S): Italian
 CASREACT 110:36649
 QI



AB The synthesis and antifungal activities of new 1,5-diarylpyrrole derivs.
 I

(R = NO2, Cl; R1 = HNC6H11, HNC12H25, HNC6H13, N-methylpiperazinyl; R2 = H, NO2; n = 1 or 2) are reported. In comparison with pyrrolnitrin, only carboxamide derivs. exhibit satisfactory antifungal activity. All the compds. show very poor antibacterial activity. The displacement of the NO2 group from the para to the meta or ortho positions of the aryl at C5 of the pyrrole ring affects the antimicrobial activity.

IT 118209-77-1P 118209-78-2P 118209-81-7P

118209-82-8P 118209-84-0P 118209-85-1P

118209-88-4P 118209-89-5P 118209-92-0P

118209-94-2P 118209-95-3P 118209-98-6P

118209-99-7P 118210-02-9P 118210-03-0P

118210-06-3P 118210-07-4P 118228-53-8P

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological

study, unclassified); SPN (Synthetic preparation); BIOL (Biological


study); PREP (Preparation)

(preparation and antimicrobial activity of)

RN 118209-77-1 CAPLUS


CN 1H-Pyrrole-3-carboxamide, N-dodecyl-2-methyl-1-(4-nitrophenyl)-5-phenyl- (9CI) (CA INDEX NAME)

L6 ANSWER 42 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 118209-78-2 CAPLUS

CN 1H-Pyrrole-3-carboxamide, N-hexyl-2-methyl-1-(4-nitrophenyl)-5-phenyl- (9CI) (CA INDEX NAME)



RN 118209-81-7 CAPLUS


CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N-dodecyl-2-methyl-5-phenyl- (9CI) (CA INDEX NAME)



L6 ANSWER 42 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 118209-82-8 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N-hexyl-2-methyl-5-phenyl- (9CI) (CA INDEX NAME)



RN 118209-84-0 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-N-dodecyl-2-methyl-5-phenyl- (9CI) (CA INDEX NAME)




RN 118209-85-1 CAPLUS

CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-N-hexyl-2-methyl-5-phenyl- (9CI) (CA INDEX NAME)


SAEED

10743642

L6 ANSWER 42 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 118209-88-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-dodecyl-2-methyl-5-(2-nitrophenyl)-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 118209-89-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-hexyl-2-methyl-5-(2-nitrophenyl)-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 42 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 118209-92-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N-hexyl-2-methyl-5-(2-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 118209-94-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-N-dodecyl-2-methyl-5-(2-nitrophenyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 42 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 118209-95-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-N-hexyl-2-methyl-5-(2-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 118209-98-6 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-dodecyl-2-methyl-5-(3-nitrophenyl)-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




L6 ANSWER 42 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 118209-99-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-hexyl-2-methyl-5-(3-nitrophenyl)-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118210-02-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N-dodecyl-2-methyl-5-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 118210-03-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N-hexyl-2-methyl-5-(3-nitrophenyl)- (9CI) (CA INDEX NAME)


SAEED

10743642

L6 ANSWER 42 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 118210-06-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-N-dodecyl-2-methyl-5-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 118210-07-4 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-N-hexyl-2-methyl-5-(3-nitrophenyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 42 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 118228-53-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N-dodecyl-2-methyl-5-(2-nitrophenyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 43 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1989:20996 CAPLUS
 DOCUMENT NUMBER: 110:20996
 TITLE: Compounds with antibacterial and antifungal activity. Part V. Synthesis and microbiological activity of new 1,5-diarylpyrrole derivatives
 AUTHOR(S): Scalzo, M.; Porretta, G. C.; Chimenti, F.; Bolasco, A.; Casanova, M. C.; Simonetti, N.; Villa, A.
 CORPORATE SOURCE: Dip. Chim. Tecnol. Sostanze Biol. Attive, Univ. "La Sapienza", Rome, Italy
 SOURCE: Farmaco, Edizione Scientifica (1988), 43(9), 677-91
 CODEN: FRPSAX; ISSN: 0430-0920
 DOCUMENT TYPE: Journal
 LANGUAGE: Italian
 OTHER SOURCE(S): CASREACT 110:20996
 GI




AB The synthesis and antifungal activities of the new 1,5-diarylpyrrole derivatives. I (R = NO₂, Cl; R₁ = HNC₆H₁₃, HNC₁₂H₂₅, N-methylpiperazinyl, cyclohexylamino; R₂ = F, Cl, Br, Me, OMe; n = 1 or 2) are reported. The N-methylpiperazinyl substituent is fundamental to activity. The presence of substituents at the para position of the two Ph rings and the presence of halogen atoms enhance microbiol. activity. The results are discussed in relation to structure-activity relationships.


IT 118179-24-1P 118179-25-2P 118179-28-5P
 118179-29-6P 118179-32-1P 118179-33-2P
 118179-36-5P 118179-37-6P 118179-40-1P
 118179-41-2P 118179-44-5P 118179-45-6P
 118179-48-9P 118179-49-0P 118179-52-5P
 118179-55-8P 118179-56-9P 118179-59-2P
 118179-60-5P 118179-63-8P 118179-64-9P
 118179-67-2P 118179-68-3P 118179-71-8P
 118179-72-9P 118179-75-2P 118179-76-3P
 118209-18-0P 118209-19-1P 118210-84-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation and antimicrobial activity of)

RN 118179-24-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-(4-fluorophenyl)-N-hexyl-2-methyl-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)


L6 ANSWER 43 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 118179-25-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-dodecyl-5-(4-fluorophenyl)-2-methyl-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 118179-28-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-5-(4-fluorophenyl)-N-hexyl-2-methyl- (9CI) (CA INDEX NAME)




SAAED


10743642

L6 ANSWER 43 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 118179-29-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N-dodecyl-5-(4-fluorophenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 118179-32-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-5-(4-fluorophenyl)-N-hexyl-2-methyl- (9CI) (CA INDEX NAME)




RN 118179-33-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-N-dodecyl-5-(4-fluorophenyl)-2-methyl- (9CI) (CA INDEX NAME)


L6 ANSWER 43 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 118179-40-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1,5-bis(4-chlorophenyl)-N-hexyl-2-methyl- (9CI) (CA INDEX NAME)




RN 118179-41-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1,5-bis(4-chlorophenyl)-N-dodecyl-2-methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 43 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 118179-36-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-chlorophenyl)-N-hexyl-2-methyl-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 118179-37-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-chlorophenyl)-N-dodecyl-2-methyl-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 43 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 118179-44-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-hexyl-2-methyl- (9CI) (CA INDEX NAME)



RN 118179-45-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-dodecyl-2-methyl- (9CI) (CA INDEX NAME)




RN 118179-48-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-bromophenyl)-N-hexyl-2-methyl-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)


SAEED

10743642

L6 ANSWER 43 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 118179-49-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-bromophenyl)-N-dodecyl-2-methyl-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 118179-52-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-bromophenyl)-1-(4-chlorophenyl)-N-hexyl-2-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 43 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 118179-55-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-N-hexyl-2-methyl- (9CI) (CA INDEX NAME)




RN 118179-56-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-N-dodecyl-2-methyl- (9CI) (CA INDEX NAME)


L6 ANSWER 43 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 118179-59-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-hexyl-2-methyl-5-(4-methylphenyl)-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 118179-60-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-dodecyl-2-methyl-5-(4-methylphenyl)-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




SAEED

L6 ANSWER 43 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 118179-63-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N-hexyl-2-methyl-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 118179-64-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N-dodecyl-2-methyl-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 118179-67-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-N-hexyl-2-methyl-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)

10743642

L6 ANSWER 43 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 118179-68-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-N-dodecyl-2-methyl-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 118179-71-8 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-hexyl-5-(4-methoxyphenyl)-2-methyl-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 43 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 118179-72-9 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-dodecyl-5-(4-methoxyphenyl)-2-methyl-1-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 118179-75-2 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N-hexyl-5-(4-methoxyphenyl)-2-methyl- (9CI) (CA INDEX NAME)


L6 ANSWER 43 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 118179-76-3 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-(4-chlorophenyl)-N-dodecyl-5-(4-methoxyphenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 118209-18-0 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-N-hexyl-5-(4-methoxyphenyl)-2-methyl- (9CI) (CA INDEX NAME)




L6 ANSWER 43 OF 43 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 118209-19-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-(2,4-dichlorophenyl)-N-dodecyl-5-(4-methoxyphenyl)-2-methyl- (9CI) (CA INDEX NAME)



RN 118210-84-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 1-(4-bromophenyl)-1-(4-chlorophenyl)-N-dodecyl-2-methyl- (9CI) (CA INDEX NAME)



SAAED

10743642

=> LOGOFF

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:Y

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

228.02

401.68

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

ENTRY

TOTAL

SESSION

CA SUBSCRIBER PRICE

-33.54

-33.54

STN INTERNATIONAL LOGOFF AT 15:06:26 ON 04 FEB 2007

SAEED

This Page is inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☒ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images problems checked, please do not report the problems to the IFW Image Problem Mailbox